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Abstract 
This prospective cohort study across 12 Canadian transplant centres evaluated the costs 
incurred by 912 living kidney donors. Expenses and resources were captured to 3-months 
post-donation, and micro-costing was used to appraise the costs incurred by donors. 
Living kidney donors incurred average total costs of $4790, and direct and indirect costs 
of $2110 and $2679, respectively. 13.3% of donors incurred total costs exceeding 
$10,000, and 8.6% of donors incurred costs >25% of their annual household income. 
Costs incurred by spousal donors were not significantly different from either unrelated or 
closely related donors. Similarly, costs incurred by kidney paired donors were not 
significantly different from other donors. In multivariable analyses, living >100 km from 
the transplant evaluation centre and being employed were associated with higher total 
costs.  In conclusion, many living kidney donors incur substantial costs associated with 
donation, and our findings can be used to improve the donation experience. 
Keywords 
Living kidney donation, kidney transplantation, cost analysis, prospective cohort study, 
micro-costing, reimbursement policy 
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Chapter 1  
1 Introduction 
Over 40,000 Canadians live with end-stage kidney disease (ESKD), a number that has 
more than doubled in the last two decades.2,3 Patients living with kidney failure have a 5-
year survival rate of just 38%: comparable to rates for many advanced cancers.4 Kidney 
transplantation is the preferred treatment for end-stage kidney disease and, compared to 
dialysis, results in increased long-term survival, improved quality of life, and reduced 
health care costs.5-7 Unfortunately, supply has not met the demand; patients wait several 
years to receive a deceased donor kidney transplant, and 2-3% of patients die waiting 
each year.8 
In response to the shortage of deceased donor kidneys, living donor kidney 
transplantation has emerged to fill in the gap, accounting for ~40% of kidney transplants 
in Canada today.9,10 Compared to deceased donation, living kidney transplants offer 
ESKD patients the measurable benefits of decreased time on dialysis and better graft 
survival.11,12 However, the number and rate of living donor kidney transplants has 
stagnated over the last decade despite growing waiting lists and the implementation of 
kidney paired donation programs across Canada.9,13 
Living kidney donors incur financial costs throughout the donation process in the form of 
direct (travel, accommodation, parking, and medication) and indirect costs (lost income 
and lost productivity).14,15 These financial costs may pose a barrier to donation for some 
candidates.16 There is consensus within the transplant community that living kidney 
2 
 
 
 
donation should be a financially neutral act and it is just that donor costs associated with 
transplantation be reimbursed.17 These costs incurred by donors occur in the context of 
their gift improving the health of the recipient, and substantial healthcare savings in 
averted dialysis costs (every 100 living kidney donor transplants over a 5-year period 
save the healthcare system about $25 million).2,18,19 Given this, many argue that the full 
extent of economic consequences to donors should be mitigated, including home and 
work productivity losses.20 The burden of these out-of-pocket costs may dissuade donors; 
presently, socioeconomically disadvantaged patients with kidney failure are less likely to 
receive a living donor kidney than wealthier patients.21 In response, Canada implemented  
its first programs to reimburse donors for their expenses in 2009; nevertheless, the 
policies that govern these programs lack evidence-based criteria and vary considerably 
across provinces.22  
Many prior efforts to describe the economic costs and financial burden of living kidney 
donation have been limited by small sample sizes, the retrospective nature of the studies, 
and incomplete or inadequate cost-capturing.15 There is an opportunity to better 
characterize the costs of living kidney donation from the perspective of the donor: a 
critical component of donor education and a truly informed consent process ensuring 
patients understand the economic consequences of donation. Given the gaps in the 
literature, there is a clear need to accurately quantify the costs of living kidney 
transplantation from the donor perspective in a rigorous prospective study. 
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   Aim and Scope 
The overarching aim of this research is to gain a holistic understanding of the economic 
costs incurred by Canadian living kidney donors. This understanding can be used to 
support informed consent, and to inform strategies that address the financial barriers to 
donation which includes an evidence-based reimbursement policy. This research uses a 
prospective design, with comprehensive cost-capturing instruments, and a sample size 
five times larger than the leading study in the field.  
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Chapter 2  
2 Literature Review 
 End-Stage Kidney Disease 
End-stage kidney disease (ESKD), or kidney failure, occurs as a result of reduction in 
renal function to a point where the kidneys are no longer able to sustain day-to-day life.23 
ESKD is the final and most severe stage of chronic kidney disease.24,25 The 2012 Kidney 
Disease Improving Global Outcomes guidelines for evaluating and managing kidney 
disease defined ESKD as a reduction in glomerular filtration rate (GFR) to less than 15 
mL/min/1.73 m2 or dysfunction necessitating renal replacement therapy (dialysis or a 
kidney transplant).25 GFR is a measure of kidney function describing the flow rate of 
filtered fluid through the kidney; a GFR is > 90 mL/min/1.73 m2 is considered normal or 
healthy.25,26 Diabetes as a cause of kidney disease is growing and accounts for nearly half 
of the primary diagnoses of Canadian patients with ESKD.9 
In a report by the Canadian Organ Replacement Register, the burden of kidney failure is 
growing; the prevalence of ESKD has increased nearly 141% since 1993 and continues to 
climb.3 By the end of 2013, over 40,000 Canadians were living with kidney failure, 
compared to less than 15,000 just 20 years earlier.2,3 Between 1993 and 2001, the 
incidence of ESKD among older patients doubled, and though these rates have stabilized 
in recent years, there were 5431 Canadians newly diagnosed with ESKD in 2012, almost 
double the number diagnosed in 1993.3 
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For all patients with incident ESKD, the 5-year unadjusted survival rate is just 38%, 
similar to the survival rates for many advanced cancers.4 In patients over the age of 65, 
the 5-year survival is only 18%.27 In 2013, more than half of incident cases of ESKD in 
Canada were among patients aged 65 and older.3 Beyond the poor mortality outcomes for 
kidney failure, patients have a markedly reduced health related quality of life.28-30 In a 
prospective study of Canadian ESKD patients, half reported problems with pain, and of 
these patients, three-quarters reported that their pain was ineffectively managed.31 
Treating kidney failure is resource intensive for both the healthcare system and for 
patients. In 2002, over 1.2% of total Canadian healthcare expenditures were devoted to 
caring for patients with ESKD, while only 0.092% of the population has kidney 
failure.32,33 Beyond this, many patients experience restrictions in their professional and 
personal lives, placing a heavy financial burden on patients, their families, and the 
healthcare system.34-36  
 Renal Replacement Therapy 
The treatment for end-stage kidney disease is renal replacement therapy (RRT), where 
the blood-filtering function of the kidneys is replaced by way of dialysis or a kidney 
transplant. The following sections will discuss the prevalent RRT modalities in Canada 
and their outcomes from the perspective of patients with kidney failure. 
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2.2.1 Dialysis 
Dialysis is a type of renal replacement therapy involving the removal of wastes and 
excess water by diffusing solutes and filtering fluid across a semi-permeable membrane. 
There are two main types of dialysis: hemodialysis (HD) and peritoneal dialysis (PD). 
Hemodialysis works by removing waste products and excess fluid from blood by 
circulating it outside the body through an external filter.37 In Canada, hemodialysis is the 
most common form of RRT: 77% of patients starting renal replacement therapy for 
ESKD in 2013 initiated treatment on hemodialysis.9 The 5-year survival rate for HD is 
44.8%, however, survival varies across patient age and primary diagnosis.9 Typically, 
patients receive hemodialysis 3-4 times a week for sessions of 3-5 hours in length. 
Transportation costs and productivity losses due to hemodialysis are a financial burden 
felt both by patients and their caregivers. A small Canadian randomized trial found that 
the overall patient-borne cost for in-centre hemodialysis is $3104 over a 6 month period, 
while the annual healthcare cost of treating a patient with HD ranges from $90,000 to 
$107,000 to the public insurer.33,38 
In peritoneal dialysis (PD), a glucose solution is passed into the peritoneal cavity to 
facilitate the removal of waste and excess fluid; the peritoneal membrane acts as the 
semi-permeable membrane.37 About 10% of Canadian ESKD patients are treated with 
peritoneal dialysis, and 19.4% initiated treatment on PD in 2013.9 Some studies (but not 
others) have suggested that peritoneal dialysis is associated with a survival advantage 
compared with in-centre hemodialysis, and in Canada, the 5-year survival rate for PD is 
54.5%.9,39-41 However, uncertainty in the relative efficacy of the two dialysis modalities 
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remains due to a lack of randomized trials comparing the two directly. Peritoneal dialysis 
is administered at home by the patient and offers more control and independence than 
hemodialysis. The overall healthcare cost of PD also appears to be appreciably less than 
that of HD, with the cost of treating a single patient at $56,000 per year.33  
2.2.2 Transplantation 
Kidney transplantation is the preferred renal replacement therapy for most patients with 
kidney failure. In 2013, 42.5% of Canadian patients living with ESKD had functioning 
kidney transplants and 3.9% of patients with kidney failure initiated therapy by way of 
transplant (referred to as a pre-emptive kidney transplant).9 
Kidney transplantation is dependent on the availability of organs from either deceased 
donors or living donors. Donor kidneys and recipients are assessed for compatibility 
based on blood typing, serum crossmatch, and histocompatibility. Unfortunately, the 
number of patients waiting for a deceased donor kidney in Canada increased 13% from 
2001 to 2012; by the end of 2013, there were 3277 Canadians on the waiting list for a 
kidney transplant.8,9 
 Deceased Donor Kidney Transplantation 
Deceased donor kidneys come from two main sources: donors who are declared brain-
dead or donors following a cardiac death. Historically, the deceased donor rate in Canada 
has varied between 12 and 14 per million population, much lower than countries with 
national donation programs, such as Spain.42 Nonetheless, deceased donor kidneys 
accounted for 61% of kidney transplants in Canada between 2004 and 2013.9 
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Compared to dialysis, deceased donor kidney transplantation substantially improves 
quality of life and confers a significant long-term survival benefit (reducing the relative 
risk of death by 64% at one year).5,6 Graft survival rates for patients receiving deceased 
donor kidneys are 94.8% at 1 year and 82.6% at 5 years after transplant.9 
 Living Donor Kidney Transplantation 
Deceased donation has not met the demand for kidneys. Living kidney donation has 
evolved substantially since the first kidney transplant between identical twins in 1954.43  
Beyond the developments in transplant surgery techniques and immunosuppression, there 
is now a better understanding of best practices to evaluate living kidney donor candidates, 
and the outcomes of living kidney donors.44 
Compared to deceased donation, living kidney transplantation offers substantial benefits 
to patients with ESKD, including decreased time on dialysis, and improved graft and 
recipient survival.11,12 Graft survival rates for patients receiving living donor kidneys are 
97.7% at 1 year and 89.2% at 5 years.9 On average, patients receiving living donor 
kidneys live 10 to 15 years longer than patients on dialysis.5 
The number of living donor kidney transplants has increased by 26% between 1998 and 
2008, representing about 40% of kidney transplants in Canada today.9,10 However, the 
number of living donor kidney transplants has stagnated since 2006, fluctuating between 
435 and 477 donations each year.9 
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 Costs of Kidney Transplantation 
The healthcare costs of living kidney donation are similar to or lower than costs 
associated with deceased donation, and substantially lower than costs associated with 
dialysis.19,45 The average cost of in-centre hemodialysis ranges from $95,000 to $107,000 
per patient per year.18,19 The average initial cost for a kidney transplant approximates 
$100,000 in the first year, and $20,000 in each subsequent year for follow-up and 
medication costs; over 5 years, each kidney transplant results in a healthcare savings of 
approximately $250,000 dollars compared to dialysis.2,7,18,19 Phrased another way, every 
100 kidney transplants result in a 5-year healthcare savings of $25 million in averted 
dialysis costs. 
A cost-utility analysis of renal replacement therapies demonstrates that, in the first year 
compared to dialysis, transplantation results in a per-patient healthcare savings of $7119 
and a net gain of 0.12 quality-adjust life-years (QALYs). Corresponding numbers in the 
second-year post-transplant are savings of $43,365 and a gain of 0.11 QALYs per 
patient.7 
 Living Kidney Donation in Canada 
In Canada, there are 18 active adult kidney transplant programs across seven provinces. 
Between 2004 and 2013, these centres performed 4417 living donor kidney transplants 
(about 500 living kidney donor transplants a year).9 The donors participating in these 
transplants include directed donors, non-directed donors, and donors participating in 
kidney paired donation. These three types of donors are described below.  
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Directed donors are those who specify the recipient to whom they intend to donate their 
kidney. In other words, they “direct” the donation. Directed donors may be genetically 
related (such as a child or sibling) or emotionally related (such as a spouse/partner or 
friend).  
Non-directed donors are those who do not specify their recipient and instead donate 
based on compatibility to a recipient selected from the waiting list (which may include 
initiating a chain of donations through kidney paired donation). The policy of several 
transplant centres is for non-directed donors to remain anonymous throughout the 
donation process (i.e. they never meet their recipient). 
An estimated one-third of willing directed donors are unable to proceed with donation 
due to incompatibility with their intended recipient.46 To address this, Canadian Blood 
Services (CBS) established the national Kidney Paired Donation Program and the 
Canadian Transplant Registry in 2009.13 Kidney paired donation (KPD) facilitates 
transplantation by matching incompatible donor-recipient pairs through n-way, domino 
chain, and paired exchanges.13 By 2011, all provinces with transplant programs were 
fully participating. The KPD Program runs a matching algorithm against donor and 
ESKD patient records in the transplant registry in four month cycles. The algorithm 
identifies potential exchanges and scores matches on variables predictive of transplant 
success.47 By the end of 2013, the program had facilitated 271 kidney transplants, with 
the number of donations per cycle growing each year.13  
Donors participating in the KPD Program face a unique set of challenges throughout their 
donation process. Regulatory frameworks enacted by Health Canada necessitate donor 
11 
 
 
 
travel to the recipient’s location for transplant, and as a result, 53% of these kidney paired 
donors have been required to travel out-of-province for surgery.13 This travel gives rise to 
a financial burden in the form of flights and accommodations, separates donors from 
loved ones at an inherently stressful time, and potentially exposes donors to language 
barriers in bilingual Canada.48,49 For these reasons, CBS has emphasized the importance 
of identifying barriers to program registration to ensure the long-term success of KPD in 
Canada.13 
The following sections serve as a critical review of living kidney donation from the 
perspective of the donor, with a focus on the economic consequences of donation. 
2.3.1 Medical Outcomes of Living Kidney Donors 
Living kidney donation is practiced under the principle that both short-term and long-
term medical risks borne by donors are outweighed by expected benefits to the recipient 
and a psychological benefit of altruism to the donor.50 However, understanding and 
quantifying these risks is paramount to guiding informed consent in donor registration 
and facilitating donor follow-up. 
The most immediate risk encountered by donors is that of surgical mortality. In a study 
drawing from over 80,000 living kidney donations in the United States between 1994 and 
2009, the 90-day surgical mortality was found to be 3.1 per 10,000 donors (95% CI: 2.0 
to 4.6).51 Other retrospective studies in Japan and Norway found similar results.52,53 
Living kidney donors face a 25-40% reduction in glomerular filtration rate following 
nephrectomy.54 There is uncertainty and debate as to whether this reduction results in 
long-term adverse outcomes, such as kidney and cardiovascular disease.55-57 Much of the 
12 
 
 
 
literature on the medical risks to living kidney donors make comparisons to the general 
population. However, donors are generally healthier as a group due to rigorous donation 
criteria and evaluation, thus understanding the risks to donors requires comparisons to 
non-donors with similar indicators of baseline good health.21 
Several studies have reported a low incidence of ESKD in living kidney donors within 10 
years post-nephrectomy, ranging from 0.2% to 0.5%.58-60 However, a study in the United 
States compared 96,217 donors (median follow-up of 7.6 years) to healthy matched 
controls (median follow-up of 15 years) and found the cumulative incidence of ESKD 
was significantly higher in the living kidney donor group (30.8 per 10,000 people, 95% 
CI: 24.3 to 38.5) compared to healthy controls (3.9 cases per 10,000 people, 95% CI: 0.8 
to 8.9).61 A similar study by Mjøen et al. found that living kidney donors had a hazard 
ratio of 11.38 (95% CI: 4.7 to 29.63) for ESKD compared to healthy non-donors.62 
When comparing outcomes of all-cause mortality and cardiovascular disease between 
living kidney donors and healthy non-donors, most studies report no differences in long-
term survival or risk of developing cardiovascular disease.51,63,64 One Norwegian study 
did report significantly higher mortality in kidney donors than in matched non-donors at 
25 years (adjusted HR = 1.3; 95% CI: 1.11 to 1.52), however, the accrual periods for 
comparator groups differed and survival differences may reflect changes in care or 
mortality trends over time.62 
A Canadian retrospective study examined pregnancy outcomes post-donation. They 
found that female living kidney donors who become pregnant post-donation were at a 
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significantly higher risk of pre-eclampsia or gestational hypertension compared to healthy 
non-donor controls (11% vs. 5%; odds ratio 2.4; 95% CI: 1.2 to 5.0).65 
No differences in risk of kidney stones requiring surgical intervention, fracture events, or 
gastrointestinal bleeding have been reported across several studies which compared living 
kidney donors to healthy matched non-donor controls.66-68 
2.3.2 Psychosocial Outcomes of Living Kidney Donors 
Psychosocial assessments are an essential component of kidney donor evaluation, 
screening, and informed consent. There is a need to identify and measure the potential 
harms and benefits of living kidney donation to donor psychological well-being.  
A systematic review of clinical practice guidelines for the screening and follow-up of 
living kidney donors identified four major domains encompassing psychosocial 
assessments: informed voluntary consent, motivation, history of mental illness or 
substance abuse, and support and coping mechanisms.69 However, the review also 
reported considerable variation between guidelines and highlighted a need for high-
quality outcome data to guide the development of consistent and evidence-based 
recommendations.69A survey of 221 transplant professionals from 40 countries noted that 
living kidney donors receive inconsistent information regarding the psychosocial and 
financial costs of donation during the informed consent process.70 
Clemens et al. performed a systematic review of studies capturing the post-donation 
psychosocial outcomes of living kidney donors, finding 51 studies assessing 5139 donors 
between 1969 and 2006.50 Only 10 of the studies followed donors prospectively to assess 
psychosocial well-being, and 20 of the 41 retrospective studies did not report average 
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times between donation and follow-up.50 Across reports, only 71% of eligible participants 
responded, and only 29 studies compared the psychosocial health of living kidney donors 
to healthy non-donor controls.50 
Despite the methodological limitations of the included studies, there was overall 
agreement in the literature: most donors reported either no change or an improvement in 
their post-donation psychosocial well-being.50 The proportion of donors experiencing no 
symptoms of depression ranged from 77% to 95% across five studies.71-75 Furthermore, a 
retrospective report by Tanrivedi et al. found that donors actually reported fewer 
depressive symptoms on the Beck Depression Inventory than non-donor controls.76 
Retrospective studies by Duque et al. and Corley et al. found that 81% and 95% of living 
kidney donors reported feeling happier post-donation.77,78 And across 17 studies, kidney 
donors were found to have comparable or better quality of life scores compared to the 
general population.50 However, not all donors experienced positive outcomes. The review 
noted that some donors experienced stress due to the financial burden of donation and 
some donors felt anxiety about their remaining kidney failing.50 Clemens et al. argued 
that further studies with appropriate control groups were necessary to better guide donor 
screening guidelines.50 
To partially address these concerns, an international multi-centre cohort study 
retrospectively assessed the quality of life of 203 living kidney donors compared to 104 
non-donor controls.79 The researchers found that, across three distinct and validated 
scales, there were no significant differences in quality of life between kidney donors and 
non-donors in both unadjusted and adjusted analyses.79 The study also reported no 
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differences between donors and non-donors in number of visits to mental health 
professionals or use of psychotropic medications.79 
A Dutch study, which criticized previous reports for the use of inappropriate control 
groups due to their retrospective nature, prospectively followed 135 living kidney donors 
matched 1:1 to individuals from the general population based on gender and baseline 
mental health.80 The authors found that kidney donors did not experience changes in 
psychological complaints and well-being from baseline to 6 months post-donation, and 
beyond this, there were no difference between donors and controls over the follow-up 
period.80 The authors concluded that post-donation short-term positive or negative 
variations in kidney donor psychosocial health did not differ from changes observed in a 
comparable population of non-donors.80 
The RELIVE Study mailed surveys to 6909 patients who donated kidneys across three 
U.S. transplant centres from 1963 through to 2005.81 The questionnaires collected 
psychosocial outcomes relating to donor experience, psychological state, and relationship 
with the recipient: 2455 (36%) of donors responded.81 The authors found that 95% of 
donors perceived their donation experience as positive overall, and 75% reported that 
donation had positively affected the donor-recipient relationship.81 However, the study 
did caution that approximately 9% of donors reported at least one negative psychosocial 
outcome, though recipient graft failure was the only significant predictor of having ≥1 
poor psychosocial outcome.81 
Though these recent studies of donor emotional well-being and quality of life support the 
safety of living kidney donation, further large and comprehensive prospective studies are 
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necessary to identify the factors associated with diminished psychosocial health and 
identify donors in need of additional education or support. 
2.3.3 Economic Outcomes of Living Kidney Donors 
Despite the measurable health benefits to recipients and cost savings to the healthcare 
system as a result of living donor kidney transplantation compared with dialysis, many 
living kidney donors face economic consequences during the donation process.14 Surveys 
of donors and prospective donors have identified financial consequences to donation as 
potential disincentives and a source of concern when making the decision to donate.82,83 
Understanding and quantifying the financial burden of donation on living kidney donors 
is critical to guiding the informed consent process and developing reimbursement policies 
that are effective and just.  
 Financial Burden to Donors 
Clarke et al. performed a systematic review of studies reporting costs associated with 
becoming a living kidney donor and found 35 studies from 12 countries that measured at 
least one cost relevant to donors.15 The authors defined direct costs as those consuming 
resources (travel, accommodation, medications) and indirect costs as those related to 
productivity losses (lost income, dependent care, housework). This contrasts with the 
prevailing view in health economic literature which characterizes direct costs as those 
borne by the health sector and patients, and indirect costs as expenses which are external 
to the patient and include intangible costs to society as a whole.84 This work focuses on 
the donor perspective, and as such we adopted the cost categories as defined by Clarke et 
al. to permit comparisons to the existing literature. In assessing study quality, the authors 
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found that 30 of the 35 studies collected cost data retrospectively, with donor recall times 
ranging from 8 weeks to 9 years.15 Only four of the studies assessed the costs incurred by 
donors as a primary objective, and none reported the cost definitions and criteria they 
employed to estimate total costs borne by donors.85-88 
The proportion of living kidney donors incurring any costs during the donation process 
ranged from 9% to 45% in 10 studies from seven countries.72,73,85,86,89-94 A retrospective 
study by Johnson et al. found that the overall costs to living kidney donors ranged from 
$0 to $28,906 with an average cost of $837 (2004 USD).73 Another retrospective study by 
Smith et al. reported costs ranging from $0 to $13,788 (2004 USD).85 Unfortunately, 
neither of the studies reported costs by expense type. 
Donors incur out-of-pocket costs for travel and accommodation during evaluation and for 
surgery, yet only four studies considered these costs explicitly.15 One study found that 
donors incurred an average of $1720 for travel and accommodation combined, with costs 
ranging from $76 to $12,579 (2004 USD).87 A Canadian study reported that 53% of 
donors paid for transportation and parking during the donation process.95 A multi-centre 
study in the United States found that 99% of donors experienced costs related to travel 
and 88% paid for accommodation during their donation experience.96 
Indirect costs were also reported. Proportions of donors with lost earnings due to 
donation ranged from 14% to 30% across three studies.73,87,95 Only two studies collected 
information on the value of income lost by donors during the donation process: a 
retrospective study by Lyons et al. reported an average loss of $3386 and a prospective 
study by Zuidema et al. found an average loss of $682 (2004 USD).87,88 No study 
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measured the value of indirect costs due to lost household productivity, however, two 
studies reported that 9-44% of donors faced costs related to caring for dependents.95,96 
Clarke et al. argued that due to the retrospective nature of the studies, lengthy timeframes 
for recall, incomplete and undetailed cost data, and poor donor response rates, the 
estimated costs to donors remain uncertain and likely to be underestimated in the 
literature.15 The authors argued that a detailed multi-centre prospective cohort study was 
necessary to comprehensively measure the costs borne by living kidney donors.15 
Since then, three prospective studies have attempted to methodically describe the costs of 
donors: one in Canada and two in the United States. 
Klarenbach et al. followed a group of 100 living kidney donors across seven Canadian 
transplant centres between 2004 and 2008.1 They prospectively collected data on costs 
and resources up to one year post-donation and comprehensively micro-costed the 
economic costs (2008 CAD). The authors reported that 96% of donors incurred costs due 
to donation, with 94% and 49% experiencing out-of-pocket expenses for travel and 
accommodation respectively.1 Among those who incurred the expense, donors reported 
an average cost of $897 (SD $1048) for ground travel, $1480 (SD $1108) for air travel, 
$1759 (SD $2567) for non-hospital accommodation, and $1780 (SD $2504) for any 
direct costs.1 One third of donors incurred costs >$3,000 throughout the donation 
process.1 The authors reported the proportions of donors experiencing expenses, resource 
consumption, and monetary value of economic consequences by cost category. 
Regrettably, due to the small sample size, the study was unable to comprehensively 
collect cost data for donors participating in kidney paired donation, donors with air travel 
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expenses, or the burden of expenses in important donor subgroups (e.g. spousal donors 
burdened with the loss of possibly two incomes). Canada is a geographically large 
country where 53% of donors participating in KPD travel outside of their province to 
donate; the inability to capture these important cost components of living kidney donation 
is an important limitation of the cost analysis performed by Klarenbach et al.13 
Two studies by Rodrigue et al. reporting findings from the Kidney Donor Outcomes 
Cohort (KDOC) Study quantified costs faced by living kidney donors, the first study 
restricted cost-capturing to the pre-donation period, with the second confined to a post-
donation window.97,98 To quantify costs associated with donor evaluation during the pre-
donation period, the authors recruited 194 living kidney donors (at the time of approval 
for surgery) and surveys were completed an average of 7 days before surgery.97 They 
collected out-of-pocket expenses and resource use to measure evaluation-related direct 
and indirect costs (USD).97 The study found that 96% of donors experienced direct costs 
during the pre-donation evaluation period, with 80% of donors reporting ground travel 
costs, 17% incurring costs for accommodation, and 14% facing air travel costs. For 
donors reporting the expense, the mean direct cost incurred during the evaluation period 
was $543 (SD $954), with the highest direct costs due to air travel (mean = $1265, SD = 
$999) and accommodation (mean = $649, SD = $862). The study found that almost one 
quarter of donors experienced total costs in excess of $1000 during the pre-donation 
period. For the second study, the authors prospectively followed 182 living kidney donors 
across six transplant centres in the United States until 12 months post-donation.98 The 
study found that 92% of donors experienced direct costs as a result of donation, with 86% 
and 23% reporting expenses related to ground transportation and lodging, respectively.98 
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Among those who incurred the expense, donors reported an average cost of $388 (SD 
$462) for ground travel, $1375 (SD $1440) for air travel, $1176 (SD $1582) for lodging, 
and $1253 (SD $1951) for any direct costs.98 One fifth of donors reported costs 
exceeding $5000, and financial burden (net financial loss divided by monthly household 
income) was significantly higher with greater travel distance, lower household income, 
and more unpaid work hours missed.98 The authors reported costs and resource use for 
both donors and their caregivers separately by cost category. Though the largest reports 
of their type, Formica et al. noted that the cohort followed by Rodrigue et al. represents 
less than 3% of donations taking place in the United States during the reporting period, 
and the study recruited heavily from a fairly limited geographic area in the northeast of 
the country.99 Beyond this, the study did not report on the burden of costs between 
important donor subgroups. 
Wiseman et al. evaluated the financial burden faced by living kidney donors in a 
subjective manner, arguing that though previous work had sought to quantify the costs, 
little had been done to appreciate the subjective magnitude of burden imposed on donors 
by these costs.100 From 2003 to 2015, the authors surveyed 1136 donors at 6 months post-
donation to assess the severity of their financial burden due to donation on a scale of 0 to 
10 (0 = no burden, 10 = extreme burden).100 The study found that among the 796 donors 
(70%) who responded, 26% reported their financial burden as moderate (≥5), while 8% 
scored their burden as ≥8.100 Interestingly, the authors found that even among those 
donors who reported no direct out-of-pocket costs, almost a quarter faced considerable 
financial burden.100  Beyond the degree of burden, 35% of donors used savings and 14% 
borrowed money from loved ones to cover the expenses associated with donation.100 The 
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RELIVE Study, a retrospective study measuring the outcomes of living kidney donors 
who donated from 1963 to 2005, found comparable results: the authors reported that 20% 
of donors judged the costs they encountered during donation to be burdensome.81 
Unfortunately, the Wiseman et al. study is limited by a low response rate, a lengthy 6-
month recall window, and a homogenous donor sample, which potentially limits the 
generalizability of their findings and underestimates the true severity of the financial 
burden faced by living kidney donors.  
To date, the studies by Klarenbach et al. and Rodrigue et al. offer the most 
comprehensive glimpses into the costs borne by living kidney donors. However, due to 
small sample sizes, limited generalizability, and incomplete cost capturing, there is an 
opportunity for a large prospective cohort study to better estimate the total costs borne by 
donors, to appreciate the differences in costs between donor subgroups, and to identify 
factors associated with higher costs and greater financial burden among living kidney 
donors. 
 Reimbursement Ethics and Policy 
Reimbursing living kidney donors for expenses incurred during evaluation, surgery and 
convalescence is justifiable and supported by a majority of transplant professionals and 
by the public at large.101,102 Many have called for the need to remove financial 
disincentives from living kidney donation to ensure equity, barrier free access, and 
justice.103-105 The overwhelming consensus for financial neutrality in living donation 
prompted the American Medical Association’s Council on Ethics and Judicial Affairs to 
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support reimbursement and differentiate it from for profit donation, which is illegal in 
most jurisdictions, including Canada.106 
In Canada, facilitation of organ donation operates under a framework of altruism, and 
provincial legislations governing donation ban the exchange of “valuable consideration” 
for donated organs.107,108 However, there is considerable debate on the complex ethics of 
valuable consideration and the policy prohibiting implementation of financial incentives 
to increase rates of organ donation.109-113 
Canadian reimbursement initiatives began in earnest with the launch of the Living Organ 
Donor Expense Reimbursement Program (LODERP) in British Columbia in 2006.114 By 
the end of 2011 all seven provinces with active kidney transplant programs had initiatives 
in place to reimburse donors for expenses encountered during the donation process. 
These programs are administered at the provincial level and facilitated by several 
organizations: Kidney Foundation of Canada (Alberta, British Columbia, Manitoba and 
Saskatchewan), Trillium Gift of Life Network (Ontario), Transplant Quebec (Quebec), 
and Legacy of Life (Nova Scotia).  
Reimbursement administered by different organizations has resulted in marked variation 
in program implementation across provinces (Table 1). Though almost all programs 
provide the same total maximum amount reimbursed, the costs reimbursed by expense 
type vary even between programs facilitated by the same organization. The variation in 
program implementation across provinces has led many to argue for an evidence-based 
national reimbursement policy with a unified strategy to reimburse donors for their 
legitimate medical expenses and remove barriers to living kidney donation.48 
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Table 1. Overview and comparison of provincial reimbursement program expense ceilings by cost category 
for provinces with adult kidney transplant centres 
Expense Type 
Maximum Amount Reimbursed (Per Week/Day/Night), CAD 
 
Province 
AB BC MB NS ON QC SK 
Travel $1500 $1500 $1500 $1500 $1500 $1500 $1500 
Parking $140 ($20/day) 
$120 
($12/day) $65 $65 
$140 
($20/day) 
$140 
($20/day) 
$120 
($12/day) 
Accommodation 
$625 
($125/night) 
$875 
($125/night) 
$910 
($130/night) 
$910 
($130/night) 
$625 
($125/night) 
$650 
($130/night) 
$875 
($125/night) 
Meals $200 ($40/day) 
$175 
($25/day) 
$225 
($25/day) 
$225 
($25/day) 
$200 
($40/day) 
$225 
($45/day) 
$175 
($25/day) 
Income $3200 ($400/week) 
$3200 
($400/week) 
$2800 
($350/week) 
$2800 
($350/week) 
$3200 
($400/week) 
$3200 
($400/week) 
$3200 
($400/week) 
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 Socioeconomic Barriers to Donation 
Evidence suggests that household income is associated with access to living donor kidney 
transplantation: a study reporting on 133 potential donors found that recipients with 
higher incomes were more likely to receive a living donor kidney, versus a deceased 
donor kidney.115  A study by Gill et al. reviewed 54,483 living donor kidney transplants 
in the United States between 2000 and 2009, and found that recipients share similar 
incomes to their donors.116 Thiessen et al. surveyed a small group of potential donors 
who had opted out of donation and found that though the reasons for withdrawing from 
donor evaluation were numerous and varied, the perceived financial burden of the 
donation process was most frequently cited as the deciding factor.117 
A study by Rodrigue et al. surveyed 456 end-stage kidney disease patients (including 
waitlisted transplant candidates, and recipients of both living and deceased donor 
kidneys) about attitudes surrounding the financial implications of donation from a 
donor’s perspective.118 Almost one-third of patients reported being told by a willing 
donor candidate that they were concerned about lost income associated with the donation 
process, and of those willing donor candidates who reported these concerns 64% did not 
complete the donor evaluation.118 In the same study, the only significant predictor of a 
willing donor candidate expressing concern for lost income was lower patient household 
income.118  
Another study suggests that the decline in living donation in the United States is in part 
due to decrements in median household income and economic pressures negatively 
influencing willingness to come forward as a living kidney donor.119 Wiseman et al. 
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found the financial burden for donors undergoing surgery during the recent economic 
recession was higher than those donating pre-recession.100 Changes in living donation in 
the past decade have varied between income groups: the disparity in living donation 
between low-income and high-income populations has widened in response to recent 
economic instability.120  
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Chapter 3 
3 Objectives and Hypotheses 
The overarching aim of this work is to conduct a comprehensive study of the costs of 
living kidney donation in Canada with the intention of describing, in detail, the costs 
borne by living kidney donors and identifying differences in expenses and financial 
burden between donor groups. This work will serve to inform donor reimbursement 
policy and generate recommendations with the aim of removing the financial 
disincentives associated with living kidney donation. The specific objectives and 
hypotheses are: 
Objective 1: To describe, in detail, the costs incurred by living kidney donors in Canada. 
Specifically, to characterize the direct, indirect, and total costs borne by Canadian living 
kidney donors throughout the transplantation process by cost category and resource type 
using a micro-costing approach. 
Objective 2: To identify differences in costs and financial burden between groups within 
the Canadian living kidney donor population. Specifically, to identify which donors face 
disproportionately higher costs, the cost categories that differ between groups, and the 
factors associated with increased financial burden. 
Hypothesis 1: We expect that, due to the retrospective nature and lengthy timeframes for 
participant recall in previous work, the existing literature exceedingly underestimates the 
true financial costs borne by donors during living kidney donation. Due to small sample 
sizes, an incomplete collection of incurred costs, and a shifting landscape with the 
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introduction of Kidney Paired Donation (KPD), we expect our cost estimates to be more 
accurate and, specifically, greater than those reported by Klarenbach et al. and Rodrigue 
et al. previously.1,98 
Hypothesis 2: We expect that, due to differences in requirements for travel and 
associated flight and accommodation costs, kidney paired donors and non-directed 
donors will have higher direct and total costs than other types of donors. We expect that, 
due to increased costs associated with lost income, care of dependents, and lost home 
productivity, living kidney donors who donate to a spouse/partner will have significantly 
higher indirect and total costs than other donor-recipient relationship groups.  
4 
 
 
 
Chapter 4 
4 Study Design and Methods 
This chapter discusses the research design and methodology common to all analyses in 
the chapters that follow. It is intended to provide an overview of the methodological 
approach and assumptions linking the study data and findings into a cohesive work.  
 Living Kidney Donor Study 
The Living Kidney Donor (LKD) Study is a CIHR-funded Canadian multi-centre 
prospective cohort study exploring the long-term outcomes of living kidney donation. 
The LKD Study recruited living kidney donors and non-donor controls from all twelve 
major transplant centres across Canada from June 2009 to December 2014 
(ClinicalTrials.gov Identifier: NCT00319579). The study protocol was approved by The 
University of Western Ontario Research Ethics Board for Health Sciences Research 
Involving Human Subjects and all participants provided informed consent (Appendix A). 
The study protocol was guided by a Pilot Phase and participants recruited into the Pilot 
Phase were rolled over into Phase II of the study. 
The LKD Study follows donor and control participants annually, with each participant 
completing surveys, blood pressure readings, and laboratory readings for a minimum of 5 
years after donation. Informed consent was obtained to perform data linkages with 
healthcare record organizations and administrative databases to collect participant data 
and to facilitate long-term follow up of donors and non-donor controls. 
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The overarching objectives of the LKD study are to improve the practice of living kidney 
donation, with an emphasis on better understanding the long-term medical risks of 
donating a kidney, the psychological effects of becoming a kidney donor, and the 
economic consequences incurred by living kidney donors throughout the donation 
process. Given that randomization is not possible for the research objectives, the 
prospective cohort design provides the highest level of epidemiological evidence 
available to answer the research questions.121 
The current work focuses on the financial burden involved in becoming a kidney donor 
and the costs of living kidney donation up to three months post-donation. Discussion of 
study methodology and the analyses in the chapters that follow are restricted to the 
outcomes of non-pilot kidney donors, as the results of the Pilot Phase have been 
published previously.1 
4.1.1 Eligibility Criteria and Recruitment 
All donors deemed eligible to donate a kidney by a nephrology team at one of the twelve 
Canadian transplant centres were eligible to participate in the study. Donors were ≥18 
years of age, and could speak and read in English and/or French. All participants were 
enrolled in the study prior to donation. Recruiting from the twelve transplant centres, 
representing all the major living kidney donor centres in Canada, helped improve study 
generalizability and meet recruitment targets (Appendix B). 
The specific recruitment process varied between participating transplant centres, as the 
living donor evaluation process differs at each centre. Nevertheless, the recruitment 
techniques across all centres included: introduction of the study to donors by members of 
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the nephrology/transplant team, use of educational materials such as handouts, 
identification of participants with the assistance of hospital coordinators, meeting with 
donor candidates during hospital visits for their evaluation, providing donors with a study 
letter of information, and obtaining informed consent. 
4.1.2 Data Collection 
The LKD Study schedule is divided into four data collection periods: pre-donation, peri-
operative period, three months post-donation, and annually post-donation (Figure 1, Part 
A). The pre-donation and post-surgery data collections were coordinated by the 
participant’s local transplant centre; all subsequent post-donation data collection was 
completed by the central interviewing facility at the London Health Sciences Centre 
(LHSC). 
Following participant recruitment and informed consent, trained research staff at each 
transplant centre provided donors with verbal and written instructions regarding study 
participation. During this recruitment visit, participants completed case report forms 
(CRF) and self-administered standardized surveys. Research staff also recorded 
participant pre-donation weight, height and blood pressure, and collected urine and blood 
specimens. Following surgery, local coordinators collected nephrologist, surgeon and 
psychosocial consult notes, results of testing during evaluation, surgical information, and 
discharge status from donor medical charts. 
At three months post-donation, research staff at the central interviewing facility sent 
participants the study case report forms and standardized surveys by mail. Before study 
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materials were mailed, participants were contacted to remind them of an upcoming data 
collection period and to verify mailing addresses. 
Annually post-donation, participants are mailed a study kit containing the case report 
forms and standardized surveys, a home blood pressure machine for recording 
measurements, and a laboratory requisition for blood work. 
Upon collection, de-identified consult notes, completed case report forms, and 
standardized surveys were entered and stored in a secure online database by local and 
central coordinators to ensure data quality and handling. Physical records were stored at 
the central interviewing facility. 
4.1.3  Retention 
Loss to follow-up is a critical barrier in prospective studies and often results in bias.122 To 
minimize loss to follow-up the LKD Study employs a number of proven retention 
strategies and a systematic procedure for late or missing data collection (Appendix C).123-
125 Other strategies include repeated contact from both local transplant centres and the 
central facility, reminder calls and letters, logos on study materials to foster a study 
identity, tokens of appreciation sent alongside mailed study kits, and courier and home 
nurse services (Figure 1, Part B).
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Figure 1. Data collection periods and retention strategies employed in the Living Kidney Donor Study 
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4.1.4 Outcome Measurement 
The scope of this work focuses solely on the economic consequences of living kidney 
donation and the financial burden borne by donors to inform policies governing 
reimbursement in Canada. As such, medical and psychosocial outcomes, though 
important, have been omitted from our discussion of the study design and methods. The 
following sections will describe the identification, collection, and measurement of 
economic outcomes for living kidney donors. 
 Economic Outcomes 
During the pilot phase, study investigators performed a systematic review of the existing 
literature on the economic costs of living kidney donation.15 Guided by this review and 
through consultation with transplantation experts, a framework was developed of all costs 
incurred by donors during the pre-donation, donation, and post-donation time periods 
(visually represented in Figure 2). The framework defined two major types of expenses 
incurred by living kidney donors: direct costs (i.e. the consumption of resources) and 
indirect costs (i.e. lost productivity). This framework and detailed cost categories guided 
the data collection of the economic consequences to donors. 
Donor economic outcomes were measured by mailed self-administered surveys at three 
months post-donation. The reasoning for this time frame is two-fold: 1) to best capture all 
costs (most economic consequences are experienced by donors within 3-months post-
donation) and 2) to limit recall bias (a 90-day period for self-reported information on 
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costs agrees well with actual records, and recollection of costs more than twelve months 
after they are incurred is likely to result in underestimates).126,127 
Detailed cost-capturing methods and the data collection tools are presented in Appendix 
D. 
 Micro-Costing Methods 
Costs incurred by donors were evaluated using the three-step micro-costing technique of 
i) identification, ii) measurement, and iii) valuation of resources (Figure 2).128 
4.2.1 Resource Identification 
Resources were identified through the economic outcomes framework as either direct or 
indirect costs, and the unit of each resource was defined. Direct costs included expenses 
for travel, accommodation, and medications. Indirect costs were associated with time and 
productivity losses including: lost income, home productivity, and caring for dependents. 
4.2.2 Resource Measurement 
The three-month economic case report form captures direct and indirect costs borne by 
donors in the form of both units of resources consumed and out-of-pocket expenses by 
category. Quantifying resource utilization in each cost category by collecting the number 
of units consumed (e.g. the number of nights spent in paid accommodation) allows for 
portability of the results, allowing for comparisons across jurisdictions.
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 Figure 2. Micro-costing mechanism applied to measure the economic consequences of living 
kidney donation from the donor perspective.  
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4.2.3 Resource Valuation 
To describe costs, resource units were assigned a value using conventional costing 
techniques and appropriate provincial or local rates and estimates (e.g. provincial age- 
and sex-specific average wage rates for unpaid days of work missed due to donation). For 
resources where no unit cost or rate was available (e.g. expenses associated with 
dependent care) donor reported out-of-pocket expenses were used instead. 
4.2.4 Direct Costs 
Direct costs were defined as the value of resources consumed during the pre-donation, 
donation, and post-donation periods. These costs included ground and air travel costs 
associated with donor evaluation, surgery and follow-up, accommodation costs during 
donor evaluation and surgery, and prescription medication costs (e.g. pain medications 
and antibiotics) post-donation. The direct cost for each donor was calculated as the sum 
of the above-mentioned cost categories. 
 Ground Travel Costs 
In the 3-month post-donation economic assessment, donors reported the number of 
round-trips to see health professionals for living donor evaluation and the transplant 
centre where these evaluations took place. The driving distance between donors’ homes 
and transplant centres was calculated using Google Maps application programming 
interface (API). The postal codes of donors and their respective centre were entered into 
the Google Maps API which produced the shortest driving distance between the 
locations. This driving distance was doubled to produce a round-trip distance-travelled, 
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which was then multiplied by the reported number of round-trips to determine the 
donor’s total driving distance during evaluation. The donor’s total driving distance was 
then multiplied by the provincial kilometric rate for their province of residence to 
estimate the total costs of ground travel (Appendix E).129 
Donors who flew to the transplant centre which they reported as the site of their 
evaluations were expected to have minimal ground travel costs; and for the purposes of 
this analysis had 0 kilometers inputted for their ground travel. 
Donors were also asked to report the number of days and total out-of-pocket expenses for 
paid parking due to ground travel for evaluation, testing, and surgery. 
 Air Travel Costs 
In the 3-month post-donation economic assessment, donors were asked if they travelled 
by airplane during the donation process. Donors who flew were asked to report the city of 
departure, the city of arrival, and the number of round-trip and/or one-way flights 
between these cities. Air travel rates were estimated using Google Flights between the 
cities of departure and arrival for either round-trip or one-way flights. The cost of air 
travel was estimated for the day of April 11, 2016, returning on April 12, 2016 (if round-
trip). Rates between cities were obtained on February 27, 2016. Rates were chosen using 
Google Flights’ price graph as follows: 1) lowest available economy-class flight 
regardless of time of departure or arrival, 2) direct flight, when available, and 3) use of 
Air Canada (Canada’s most popular domestic airline), when available. Air travel rates 
included taxes and fees. 
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Air travel rates were then multiplied by the appropriate number of round-trip or one-way 
flights for each donor. The total air travel cost for each donor was the sum of the cost of 
flights during the donation process. Donors were also asked to report if air travel 
expenses were incurred by family/friends while accompanying them during the donation 
process (yes/no). 
 Accommodation Costs 
All accommodation costs were captured in the 3-month post-donation economic 
assessment. 
Donors reported the number of nights spent in paid accommodation during the evaluation 
and donation process. The three hotels nearest the hospital where each donor’s surgery 
took place were identified using Google Maps “hotels nearby” function. Hotel rates were 
chosen using the following criteria: 1) single occupancy room, 2) lowest available rate, 
and 3) accommodation for the night of April 11, 2016. Rates for three hotels per hospital 
were obtained on February 27, 2016. Rates were averaged across the three hotels per 
hospital, and appropriate federal taxes, provincial taxes, and municipal destination 
marketing fees were applied (Appendix E). The average rates (with taxes) were 
multiplied by the number of nights in paid accommodation for each donor to determine 
the total cost of paid accommodation. 
Donors were asked to report the number of nights and total out-of-pocket expenses 
related to staying with family and/or friends throughout the donation process.  
Donors were asked to report the number of nights and total out-of-pocket expenses 
related to staying in hospital (e.g. cable, telephone etc.) for testing and/or surgery.  
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Total accommodation cost for each donor was the sum of the cost of paid 
accommodation, the total out-of-pocket expenses for staying with family and/or friends, 
and the total out-of-pocket expenses related to staying in hospital. 
 Medication Costs 
In the 3-month economic assessment, donors were asked to estimate their total out-of-
pocket costs for medications prescribed because of donating their kidney. Donors were 
not asked to report the type or duration of prescribed medications; therefore, self-reported 
out-of-pocket expenses were used as the estimate for medication costs.  
4.2.5 Indirect Costs 
Indirect costs were defined as the value of time sacrificed and productivity losses during 
the pre-donation, donation, and post-donation periods. These costs included lost income 
due to unpaid days of missed work, productivity losses associated with household and 
domestic activities, and productivity losses associated with caring for dependents. The 
indirect cost for each donor was calculated as the sum of the above-mentioned cost 
categories. 
 Lost Workforce Productivity 
In the 3-month economic assessment, donors were asked to report the number of days or 
part days they were unable to work following donation (if they were employed) and the 
number of these days that were unpaid. The number of unpaid days away from work was 
multiplied by an 8-hour work-day. We then multiplied the number of hours of lost pay by 
the 2016 (age-, sex-, and province-specific) average wage rates from the Labour Force 
Survey to estimate lost workforce productivity due to donation (Appendix E).130 We did 
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not collect donor reported wage rates due to the invasiveness of the question and 
anticipated poor response rate. The human capital approach and use of average wage 
rates are suggested by the Canadian Agency for Drugs and Technologies in Health’s 
guidelines for economic evaluations, have been used previously in the evaluation of the 
costs incurred by living kidney donors, and are frequently used in health economic 
evaluations to estimate workforce productivity.1,130,131 In accordance with Drummond et 
al.’s recommendations based on equity concerns in estimating productivity losses, a 
sensitivity analysis using 2016 average provincial wage rates to value lost wages was 
performed: the results did not change (Appendix E).84,132  
 Lost Non-Workforce Productivity 
All productivity losses were captured in the 3-month economic assessment. Our 
assessment did not include opportunity costs. 
Donors were asked to report the number of days they were unable to perform household 
activities (e.g. housework, shopping etc.) and their total out-of-pocket expenses related to 
these productivity losses (e.g. cost of housekeeping) even if they were fully or partially 
reimbursed.  
Donors were asked to report the number of days they were unable to care for dependents 
(e.g. children, spouse etc.) and their total out-of-pocket expenses related to these 
productivity losses (e.g. cost of a babysitter) even if they were fully or partially 
reimbursed. 
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4.2.6 Inflation 
As donor reported out-of-pocket expenses for paid parking, staying with family and/or 
friends, hospital accommodation, prescription medication, and productivity losses were 
incurred by donors between the years 2009 and 2015, the total costs for these categories 
were standardized to the year 2016 using inflation rates (based on Canada’s Consumer 
Price Index) according to each donor’s year of surgery (Appendix E).133 Lost wages were 
estimated using the year 2016 age-, sex- and province-specific average wage rates and 
ground travel was estimated using year 2016 provincial kilometric rates. 
 Study Characteristics  
The purpose of this research is to describe the economic consequences of living kidney 
donation (the financial burden borne by donors). The primary analyses are driven by data 
collected during the 3-month post-donation assessment. The following section describes 
power and sample size considerations, follow-up of study participants, and characteristics 
of responders and non-responders. 
4.3.1 Power and Sample Size 
The primary outcome of the Living Kidney Donor Study is the risk of hypertension many 
years after donation between donors and controls. As such, power and sample size 
considerations for recruitment were calculated to detect a minimal clinically important 
effect in the outcome of hypertension. However, the 95% confidence intervals for the 
costing estimates do provide a plausible range of where the true parameter may lie. As 
shown in the results, most cost comparisons have an upper or lower bound with no more 
than a difference of $1000.  
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4.3.2 Participant Recruitment and Follow-Up 
During the recruitment period, a total of 1042 living kidney donors were recruited into 
the study (Figure 3). 
Of the 1042 donors recruited, 73 pilot donors and 57 donors who completed their 
evaluation or surgery outside of Canada were excluded from our analysis, leaving 912 
eligible donors. 
Figure 3 LKD study participant flow diagram for donors. Excluded pilot 
patient results are reported elsewhere.1 Donors missing all 3-month 
economic data were included in multiple imputation analyses.  
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4.3.3 Participant Characteristics 
We compared donors who provided some or all 3-month economic data (responders) to 
those who were missing all 3-month economic data (non-responders) across demographic 
variables collected during the recruitment assessment (Table 2). Differences between 
responders and non-responders were assessed using t-tests for means, Fisher’s exact tests 
for proportions, and Wilcoxon rank-sum tests when the outcome distribution was skewed. 
For all comparisons, p-values < 0.05 were considered statistically significant.  
Table 2. Baseline characteristic of donors who partially or fully completed the 3-month 
economic assessment compared to those donors missing all their 3-month data. 
 
 
Baseline Characteristics 
Donors reporting 
 3-month data  
 
(n = 821) 
Donors missing all 
3-month data  
 
(n = 91) 
p-value 
Age, years, mean (SD)1 47.7 (11.3) 40.9 (11.0) <0.001 
Women, n (%) 555 (68%) 54 (59%) 0.127 
Distance from home to transplant centre where 
evaluated, kilometers, median (p25, p75) 
58.9  
(18.2, 195.0) 
57.2  
(23.3, 221.0) 0.500 
Province of transplant centre, n (%)   0.641 
 Alberta 115 (14%) 18 (20%)  
 British Columbia 251 (30%) 24 (26%)  
 Manitoba 32 (4%) 5 (5%)  
 Nova Scotia 38 (5%) 4 (4%)  
 Ontario 344 (42%) 35 (38%)  
 Quebec 41 (5%) 5 (5%)  
Donation type, n (%)   0.039 
 Non-directed 36 (4%) 1 (1%)  
 Emotionally related 289 (35%) 27 (30%)  
 Genetically related 385 (47%) 56 (62%)  
 Paired 111 (14%) 7 (8%)  
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Baseline Characteristics 
Donors reporting 
 3-month data  
 
(n = 821) 
Donors missing all 
3-month data  
 
(n = 91) 
p-value 
Donor’s relationship to recipient, n (%) 0.131 
 Parent 114 (14%) 14 (15%)  
 Son/daughter 68 (8%) 10 (11%)  
 Sibling 181 (22%) 30 (33%)  
 Partner/spouse 129 (16%) 9 (10%)  
 Friend/acquaintance 93 (11%) 11 (12%)  
 Other (related) 38 (5%) 4 (4%)  
 Other (unrelated) 51 (6%) 5 (5%)  
 Don’t know the recipient who received kidney 147 (18%) 8 (9%)  
Marital status, n (%)   <0.001 
 Currently married 543 (66%) 40 (44%)  
 Common law/living with partner 110 (13%) 16 (18%)  
 Never married 91 (11%) 16 (18%)  
 Divorced 44 (5%) 8 (9%)  
 Separated 22 (3%) 9 (10%)  
 Widowed 11 (1%) 2 (2%)  
Employment status, n (%)   <0.001 
 Employed full-time 518 (63%) 60 (65%)  
 Employed part-time 114 (14%) 9 (10%)  
 Homemaker 35 (4%) 4 (4%)  
 Student 7 (1%) 1 (1%)  
 Temporary sick leave or disability 17 (2%) 5 (5%)  
 Unemployed 29 (4%) 11 (12%)  
 Retired  87 (11%) 1 (1%)  
 Other 14 (2%) 1 (1%)  
Highest level of education completed, n (%)    <0.001 
 Primary school 15 (2%) 7 (8%)  
 Secondary school 241 (29%) 47 (52%)  
 Trade school 53 (6%) 8 (9%)  
 College 215 (26%) 18 (20%)  
 University 297 (36%) 11 (12%)  
Race, n (%)    0.003 
 White 720 (88%) 69 (76%)  
 Non-white 101 (12%) 22 (24%)  
1 age at time of surgery 
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There were no significant differences in between responders and non-responders on the 
following baseline characteristics: proportion of women, the province where transplant 
evaluation occurred, donor relationship to their recipient, and distance from home to 
transplant centre. 
Responders were older than non-responders (mean 47.7 vs. 40.9 years; p < 0.001) and a 
higher proportion of responding donors were white (88% vs. 76%; p = 0.003). At 
recruitment, responders also significantly differed from non-responders in marital status 
(p < 0.001), employment status (p < 0.001), donation type (p = 0.039), and highest level 
of education completed (p < 0.001). 
 Data Quality and Handling 
The following sections describe methods used to ensure data quality and handle missing 
data.  
4.4.1 Data Screening and Cleaning 
We systematically screened data for outlying, discrepant, and missing values to ensure 
data validity, consistency, and completeness. All variables included in the micro-costing 
approach were screened to ensure values fell within a plausible range. Database case 
report forms were checked against physical survey records to identify potential data entry 
and typographical errors (e.g. postal codes where a “0” is mistakenly inputted as “O”). 
Survey skip patterns were screened (for nested questions with conditional responses) to 
ensure reported values were consistent with previous answers. Multiple attempts were 
made to contact donors (by phone, mail, and email) to recover any missing data via 
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structured interviews and to verify discrepant values. Alternate contacts were telephoned 
for updated donor contact information if information on record was no longer current. 
Any remaining missing values were abstracted from nephrologist, surgeon and 
psychosocial consult notes wherever possible. Statistical methods to deal with missing 
data are described in detail in the following section. 
4.4.2 Missing Data 
Of the living kidney donors eligible for analysis of economic outcomes, 90% completed 
the 3-month economic assessment (responders). Within the responder group, less than 
2% of variables employed in our micro-costing approach for both direct and indirect 
costs were missing. Complete-case analysis (CCA) involves the listwise deletion of cases 
where any micro-costing variables are missing. CCA was available for direct costs and 
indirect costs in 96% and 95% of responders, respectively. Complete-case analysis was 
available for total costs (the sum of direct and indirect costs) in 93% of responders (Table 
3).  
Three mechanisms to missing data have been described: missing completely at random 
(MCAR) in which the missingness is unrelated to the value of any variables, missing at 
random (MAR) in which the missingness is dependent upon observed variables only, and 
not missing at random (NMAR) in which the missing values are related to unobserved 
variables.134 Missing data in our study was assumed to be missing at random. Data MAR 
can be entirely accounted for by the observed variables (with complete information) and 
is not associated with unobserved values.135 As complete-case analysis may result in 
biased estimates if the complete and missing cases systematically differ, multiple 
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imputation (MI) was used to impute variables used in the micro-costing approach in both 
the incomplete cases and in the 10% of donors missing all three-month data (non-
responders).136 Multiple imputation has been used widely in cost-effectiveness research to 
impute missing or incomplete resource utilization and cost data.137 
The multiple imputation approach implemented was informed by the pattern of missing 
data. Faria et al. recommends imputing at the resource level (rather than the total cost 
level) when different types of resources have different patterns of missingness.138 In light 
of this recommendation, and in order to report costs and resource consumption across 
groups, variables in the micro-costing approach were imputed at the disaggregate rather 
than the aggregate level.138 For example, if a donor was missing the number of ground 
trips to a transplant centre, we imputed this value, instead of imputing the cost of ground 
travel.  
Table 3. Frequency of missing variables used in micro-costing by responder group. 
 
 Missingness, n (%) 
Variable Responders  (n = 821) 
Non-Responders  
(n = 91) 
Total  
(n = 912) 
Direct Costs    
Number of Trips 9 (1.1%) 91 (100%) 100 (11.0%) 
Nights in Hotels 4 (0.5%) 91 (100%) 95 (10.4%) 
Hospital Costs 12 (1.5%) 91 (100%) 103 (11.3%) 
Friends/Family Accommodation Costs 8 (1.0%) 91 (100%) 99 (10.9%) 
Parking Costs 13 (1.6%) 91 (100%) 104 (11.4%) 
Medication Costs 13 (1.6%) 91 (100%) 104 (11.4%) 
Indirect Costs    
Days Off Without Pay 16 (1.9%) 91 (100%) 107 (11.7%) 
Unable to Care for Dependents Costs 27 (3.3%) 91 (100%) 118 (12.9%) 
Unable to Perform 
Household Activities Costs 28 (3.4%) 91 (100%) 119 (13%) 
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There are two principal approaches to multivariate multiple imputation: joint modeling 
and multiple imputation by chained equations (MICE).139 Joint modeling imputes all 
missing values concurrently, often using a multivariate normal distribution.139-141 
Multiple imputation by chained equations is a pragmatic method to deal with missing 
data occurring in several variables; the approach is based on a series of imputation 
models, one for each of the imputed variables.140 There is no consensus recommendation 
in the literature for choice of approach. We opted to employ MICE due to its suitability 
for the missingness within our dataset and its flexibility for handling different types of 
variables and distributions because each uses its own model for imputation.142 In our 
analyses, multiple imputation was performed in Stata 14.2 which allows for MICE using 
the mi impute chained command.139,143  
Missing binary variables (e.g. did the donor travel by plane) in our dataset were modeled 
using logistic regression. Missing count variables (e.g. number of nights in paid 
accommodation) were modeled using Poisson regression. Ordinal variables (e.g. severity 
of post-operative complications) were modeled using ordered logit regression.  
As out-of-pocket costs are non-normally distributed continuous variables (right-skewed), 
we used predictive mean matching (PMM) to impute donor reported expenses (e.g. cost 
of prescription medication). Predictive mean matching generates imputed values by 
sampling from observed values, and as such the underlying distribution of the imputed 
values matches closely with that of observed ones.142,144 Each imputed value is randomly 
drawn from the observed values of a number of “nearest neighbours” (k) with predictive 
means similar to the missing observation (as determined by linear regression).139 Based 
on a simulation study, Morris et al. advocate for drawing from a pool of k = 10 donors.145 
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Vroomen et al. demonstrated the validity of PMM in imputing missing cost data by 
generating incomplete datasets from a complete reference dataset, imputing missing 
costs, and comparing imputed values to the reference dataset.146 
We followed Stata’s guidelines in the building of imputation models; the reference 
manual recommended using as many predictors as possible in the model (the 
demographic and derived variables collected during the recruitment assessment), 
including any cluster identifiers in the model (i.e. location of donor evaluation), and 
inclusion of all variables used in later analyses (including dependent variables).139 These 
variables were complete for non-responders. Models were evaluated separately for 
convergence and fit before being added to the MICE command. 
White et al. argue that the number of imputations should be at least as many as the 
percentage of incomplete cases (in our analysis this is ~15), while the Stata 
documentation recommends generating 20 imputations to reduce sampling error.139,142 To 
be conservative, we used 20 imputations.  Stata automatically combines multiply-imputed 
datasets according to Rubin’s rules during analysis and when generating estimates using 
the command mi estimate.147 According to Rubin’s rules, estimates are calculated for 
each imputed dataset and the overall point estimate is the mean of these values, while the 
standard errors are combinations of within-imputation and between-imputation 
variance.147 
Diagnostics of the multiply-imputed data were performed using the Stata command 
midiagplots which allows for efficient comparisons of the distributions of imputed 
and observed values to identify problems with the imputation model (Appendix F). 
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 Statistical Analyses 
The following sections will describe, in detail, the statistical methods and analyses 
performed in this work.  
Analyses were conducted on both multiple-imputed and complete-case datasets and 
estimates for each were reported (Appendix H). Descriptive statistics for incurred costs 
and resource use were reported separately for i) donors who reported the outcome and ii) 
all donors. Statistical tests were two-tailed using a significance level of 0.05 and analyses 
were conducted using Stata Release 14.2 (StataCorp LP, College Station, TX).  
4.5.1 Univariate Cost Analysis 
Univariate analysis of costs incurred by living kidney donors was conducted between pre-
specified groups of donors to identify differences in economic outcomes. The primary 
analyses compared direct, indirect, and total costs between donation-type groups: non-
directed donors and kidney paired donors vs. all other donors, and relationship-type 
groups (among donors not participating in non-directed or kidney paired donations): 
spousal donors vs. closely-related donors (sibling, parent, child) and unrelated donors 
(friends, acquaintances, other).  
The distribution of cost data is generally right skewed, as costs cannot be negative and 
patients with complicated cases may face substantially higher costs and use more 
resources.148,149 In light of this, median costs are routinely used to describe cost data. 
However, in economic evaluations, the arithmetic mean is of chief interest because of its 
utility to policy and decision makers.149-151 Stata’s sktest for normality was used to 
assess skewness and kurtosis of cost distributions.143 Due to the skewed nature of our cost 
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data and in effort to report our findings pragmatically, incurred expenses were reported as 
means (standard deviation) and medians (25th percentile, 75th percentile). Costs were 
compared to the common maximum provincial reimbursement amount of $5500 and the 
proportion of donors incurring costs greater than this limit was reported. Resource 
consumption and counts were reported as medians (25th to 75th percentiles). 
 Bootstrapping 
There are several approaches to conduct univariate analyses of costs with skewed 
distributions. Parametric methods such as the t-test and ANOVA are common in the 
literature, however, there are no precise thresholds for the minimum sample sizes and 
maximum skewness necessary to ensure the reliability of these tests.149,152 Non-
parametric tests such as the Wilcoxon rank-sum have found utility as alternatives to 
parametric methods, but they merely describe differences in the cost distributions and 
medians between groups and not necessarily the arithmetic mean.149,151,153 Logarithmic 
transformation of cost data has been commonly employed in healthcare cost research to 
approximate normality and conduct parametric tests on transformed scales, however, 
concerns about zero costs, inferences on the geometric rather than the arithmetic mean, 
and retransformation with smearing factors make these methods unwieldly.149  
To compare costs between groups, we calculated arithmetic means and mean differences, 
and employed non-parametric bootstrapping to build confidence intervals (CIs) for these 
measures. The non-parametric bootstrap technique avoids assumptions of the distribution 
and many of the problems encountered with other parametric and non-parametric tests of 
costs.149 Point estimates of the arithmetic mean and mean differences are calculated 
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directly from the cost data and bootstrapping provides measures of variability, including 
95% confidence intervals.149 In brief, the bootstrapping approach takes repeated random 
draws of the observed data (samples of the same size with replacement) and generates a 
series of resamples. The statistic of interest (in our case the arithmetic mean and 
difference in mean cost) can be calculated from each resample, and the distribution of 
this statistic from the resamples can be used to calculate 95% confidence 
intervals.149,154,155 Efron and Tibshirani recommend that at least 1000 resamples are 
necessary to obtain bootstrap confidence intervals, and thus 1000 repetitions were 
conducted.155,156 Bias-corrected and accelerated (BCa) bootstrap confidence intervals 
perform better than standard percentile approaches and correct for skewness; we reported 
the arithmetic means and mean differences of costs between groups with BCa 95% 
confidence intervals.154,157,158  
4.5.2 Multivariable Cost Analysis 
Multivariable analysis was used to obtain adjusted comparisons of direct, indirect, and 
total incurred expenses between donation-type groups and relationship-type groups.  
Secondary analyses were conducted to describe the direct, indirect, and total costs 
incurred by donors across sociodemographic variables, including sex, age at time of 
nephrectomy (18-34 years vs. 35-54 years vs. 65+ years), distance from transplant center, 
race (white vs. non-white), income, employment status (employed vs. unemployed vs. 
retired vs. other), and province of transplant centre. 
Trends in counts (e.g. number of visits) and skewed continuous variables (e.g. costs) 
across groups were evaluated using Stata’s nptrend command: a non-parametric test for 
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trends across ordered groups. The test functions as an extension of the Wilcoxon rank-
sum test and is intended for scenarios where a variable is measured across more than two 
groups.159 
 Generalized Linear Models 
Using multivariable models to analyze costs does not avoid the same distributional issues 
of heavily skewed cost data encountered in univariate analyses. Ordinary least squares 
(OLS) regressions of untransformed and transformed costs, though the most common 
approaches to cost analysis, face problems with violations of the assumptions of 
homoscedasticity and normally distributed error terms, and problems with 
retransformation.149,152 
Generalized linear models (GLM) have become increasingly used as an alternative to 
OLS models to analyze costs.149 GLMs have emerged because of the flexibility they offer 
in allowing mean and variance to be directly specified, and because they avoid 
distributional problems in cost analysis, as mean and variance can be modelled on the 
original scales.149,160 To employ GLMs in cost analysis we determine a link function and 
a family based on the data. The link function describes how the mean on the original scale 
is related to the linear combination of the coefficients and regressors in the model, and so 
does not face issues of retransformation.149,160 The log link has been used widely in 
healthcare cost literature as it predicts the log of the mean, and thus, exponentiation of the 
predictions from the GLM to arrive at the arithmetic means does not require smearing 
factors.149 Specification of a distributional family reflecting the mean-variance 
relationship allows for heteroscedasticity to be modelled.160 For example, the gamma 
family specifies the variance as being proportional to the square of the mean.160 
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Misspecification of the link function and family may affect model fit, and result in 
inefficient and biased parameter estimates.160 For our multivariable analysis, the choice 
of link function was guided by the Stata program glmdiag which performs the Pregibon 
linktest, Pearson’s correlation test, and the modified Hosmer-Lemeshow test.161-163 
Specification of the distributional family was informed by the modified Park test.164 
Candidate families assessed included: Gaussian (constant variance), gamma (variance 
proportional to square of the mean), Poisson (variance proportional to the mean), and 
inverse Gaussian (variance proportional to cube of the mean).149 The results of model 
diagnostic and goodness of fit tests are reported in Appendix G. Following these 
diagnostic tests for link function and family, we employed a GLM with a log link and 
gamma distribution to elicit adjusted comparisons of donor expenses between groups, a 
specification commonly used in health economic literature to model costs.160  
Deviance residuals were assessed using normal plots to judge goodness of fit for our 
model.160,165 The Stata program collin, which provides variance inflation factors, 
tolerance, and condition index, was used to detect multicollinearity across 
covariates.143,166 
 Average Marginal Effects 
Glick et al. cautioned that, with multiplicative models such as GLM, non-linear 
retransformations when estimating costs can introduce covariate imbalances.149 To 
overcome this problem, the authors recommend estimating differences between groups as 
incremental costs using the technique of recycled predictions.149 Recycled predictions 
generate an identical covariate structure for each group by treating each observation as if 
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they were in one group, predicting costs, and then treating each observation as if they 
were in the comparison group, and again predicting the cost for each.149,167 Differences in 
the costs between individual observations reflect the marginal effect of being in the 
comparison group; the average of these individual effects results in an average marginal 
effect (AME) comparing costs between groups while holding all other covariates 
constant.167 Stata performs recycled predictions using the margins and mimrgns 
commands.143 
To report the results of the multivariable analysis, we performed pairwise recycled 
predictions between referent and comparator groups to calculate the adjusted AMEs (as 
differences in indirect, direct, and total costs between demographic groups, donation-type 
groups, and relationship-type groups), along with their 95% confidence intervals and p-
values. 
 Covariate Selection 
The analyses were adjusted for a set of covariates identified using a theory driven 
approach relying on previous literature and clinical judgement. Analyses were adjusted 
for age, sex, post-operative complications, income, and transplant centre. 
Age and sex are well characterized determinants of healthcare expenditures and resource 
utilization.168,169 Beyond this, previous reports characterizing patient direct medical 
expenses and identifying predictors of cost have adjusted for age and sex in multivariable 
analyses.170,171 To be consistent with the literature we included donor sex and age at the 
time of surgery as covariates in our model. 
Donor complications are associated with lengthier hospital stays, a higher probability of 
hospital readmission, greater use of post-discharge medications, and increased healthcare 
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costs.172-174  In light of this, donor complications may result in prolonged time off work, 
increased number of visits to healthcare professionals, and medication costs covered by 
the donor. A study by Wiseman et al. found that operative outcomes had a significant 
impact on financial burden.100 As a result, we included donors’ Clavien-Dindo 
classification as a covariate in our model to adjust for post-operative complications. The 
Clavien-Dindo system is a tool that ranks surgical complications based on the therapeutic 
intervention necessary to correct the complication.175 Clavien-Dindo grades were 
abstracted from donor surgical notes and discharge summaries. 
A report by Sanmartin et al. found that, from 1998 to 2009, out-of-pocket healthcare 
expenditures increased for all Canadian households, but the increases were greater among 
Canadians in the lower income quintiles.176 The authors argued that this cost burden can 
result in a reduced use of healthcare services.176 Therefore, self-reported household 
income of donors was included in our multivariable model. 
Our prospective cohort study recruited donors from 12 transplant centres across Canada 
and variations in donor selection criteria, evaluation, and follow-up cannot be ruled out. 
To account for potential variation in practice patterns between centres and generate 
robust standard errors that allow for intragroup correlation, we specified the transplant 
centre of donor evaluation as the cluster variable used in Stata’s variance estimator for 
multivariable analyses.143 
 STROBE Statement and Checklist 
This work, including its reporting, adheres to the recommendations of the STrengthening 
the Reporting of OBservational studies in Epidemiology (STROBE) initiative, statement 
and checklist for cohort studies. (Appendix I).177 
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Chapter 5 
5 Results 
 Descriptive Statistics 
This section reports the demographic characteristics and economic outcomes of our 
cohort of Canadian living kidney donors. Specifically, it describes the direct, indirect, and 
total costs incurred and resources consumed by donors throughout the living donation 
process by cost category and resource type. Differences in demographic characteristics 
between groups were assessed using analysis of variance for means, and Fisher’s exact 
tests for proportions. For all comparisons, p-values < 0.05 were considered statistically 
significant.  
5.1.1 Demographic Characteristics 
The demographic characteristics of study participants are presented in Table 4. Most 
living kidney donors enrolled in the study (n = 912) were recruited at transplant centres in 
two provinces: British Columbia (30%) and Ontario (42%). The average age at the time 
of donation was 47.0 years, and most donors were women (67%) and white (87%). 
Donors underwent transplant surgery between 2009 and 2015, and at the time of surgery, 
64% were married, 77% were employed, and 60% lived less than 100 km from their 
transplant centre. Most donors had completed university as their highest level of 
education (34%), followed closely by secondary school (32%) and college (26%). 
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Among the 668 donors reporting income, 35% had an annual household income greater 
than $100,000 (CAD). In relation to their recipients, donors were most commonly 
siblings (23%), followed by spouses/partners (15%), parents (14%), friends (11%), and 
sons/daughters (9%) of their recipients. In total, 17% of all donors participated in either 
kidney paired (13%) or non-directed (4%) donations, and as such did not know the 
recipient who received their kidney. 
 Donation-Type Groups 
Donor characteristics were generally similar across donation-type groups; exceptions 
include differences in racial makeup (proportion of white donors: non-directed = 100% 
vs. kidney paired = 86% vs. all others = 85%, p = 0.02) and age: kidney paired donors 
were significantly older than all other donors at the time of surgery (49.9 years vs. 46.5 
years, p = 0.01). 
 Relationship-Type Groups 
Although donors across relationship-type groups were mostly similar with respect to 
demographic characteristics, there were significant differences across the three groups in 
the proportion of female donors (spousal = 81% vs. closely related = 63% vs. unrelated = 
66%, p < 0.001) and in donor racial makeup (proportion of white donors: spousal = 88% 
vs. closely related = 82% vs. unrelated = 92%, p = 0.004). Additionally, at the time of 
surgery, spousal donors were significantly older than both closely related and unrelated 
donor groups (49.6 years vs. 46.0 years and 45.4 years respectively, p = 0.001).   
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Table 4. Demographic characteristics of living kidney donors. 
Variable 
   Donation-type group (N = 912) 
 Relationship-type group 
(N = 757)2 
 All donors 
(N = 912) 
 Non-directed donors 
(n = 37) 
Kidney paired 
donors 
(n = 118) 
All other donors 
 (n = 757) 
 Spousal donors 
(n = 138) 
Closely related 
donors 
(n = 417) 
Unrelated donors 
(n = 202) 
Age at donation, years, mean 
(SD) 
 47.0 (11.5)  47.6 (12.9) 49.9 (10.7) 46.5 (11.4)  49.6 (10.7) 46.0 (11.9) 45.4 (10.6) 
           
Female, n (%)  609 (67%)  24 (65%) 78 (66%) 507 (67%)  112 (81%) 261 (63%) 134 (66%) 
Race, n (%)           
    White  789 (87%)  37 (100%) 101 (86%) 651 (86%)  121 (88%) 344 (82%) 186 (92%) 
Year of surgery, n (%)           
     2009  3 (0%)  0 (0%) 0 (0%) 3 (0%)  1 (1%) 0 (0%) 2 (1%) 
     2010  132 (14%)  3 (8%) 10 (9%) 119 (16%)  20 (14%) 72 (17%) 27 (13%) 
     2011  180 (20%)  5 (14%) 15 (13%) 160 (21%)  26 (19%) 85 (20%) 49 (24%) 
     2012  209 (23%)  8 (22%) 21 (18%) 180 (24%)  31 (22%) 103 (25%) 46 (23%) 
     2013  222 (24%)  11 (30%) 45 (38%) 166 (22%)  32 (23%) 91 (22%) 43 (21%) 
     2014  165 (18%)  10 (27%) 27 (23%) 128 (17%)  28 (20%) 65 (16%) 35 (17%) 
     2015  1 (0%)  0 (0%) 0 (0%) 1 (0%)  0 (0%) 1 (0%) 0 (0%) 
Marital status, n (%)            
     Married  583 (64%)  20 (54%) 86 (73%) 477 (63%)  120 (87%) 249 (60%) 108 (53%) 
     Common-law/living with 
partner 
 126 (14%)  7 (19%) 17 (14%) 102 (13%)  18 (13%) 52 (12%) 32 (16%) 
     Separated or divorced  83 (9%)  4 (11%) 6 (5%) 73 (10%)  0 (0%) 42 (10%) 31 (15%) 
     Never married  107 (12%)  6 (16%) 8 (7%) 93 (12%)  0 (0%) 65 (16%) 28 (14%) 
     Widowed  13 (1%)  0 (0%) 1 (1%) 12 (2%)  0 (0%) 9 (2%) 3 (1%) 
           
Donor evaluation <100 km of 
home, n (%) 
 546 (60%)  21 (57%) 67 (57%) 458 (61%)  85 (62%) 255 (61%) 118 (58%) 
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Variable 
   Donation-type group (N = 912) 
 Relationship-type group 
(N = 757)2 
 All donors 
(N = 912) 
 Non-directed donors 
(n = 37) 
Kidney paired 
donors 
(n = 118) 
All other donors 
 (n = 757) 
 Spousal donors 
(n = 138) 
Closely related 
donors 
(n = 417) 
Unrelated donors 
(n = 202) 
Employment status, n (%) 
     Employed (full-time)  578 (63%)  18 (49%) 79 (67%) 481 (64%)  70 (51%) 275 (66%) 136 (67%) 
     Employed (part-time)  123 (13%)  10 (27%) 16 (14%) 123 (13%)  25 (18%) 46 (11%) 26 (13%) 
     Retired  87 (10%)  2 (5%) 13 (11%) 72 (10%)  21 (15%) 38 (9%) 13 (6%) 
     Other  124 (14%)  7 (19%) 20 (17%) 107 (14%)  22 (16%) 58 (14%) 27 (13%) 
Education level, n (%)           
     Primary School  22 (2%)  0 (0%) 3 (3%) 19 (3%)  3 (2%) 11 (3%) 5 (2%) 
     Secondary school  288 (32%)  10 (27%) 27 (23%) 251 (33%)  41 (30%) 139 (33%) 71 (35%) 
     Trade school  61 (7%)  1 (3%) 8 (7%) 52 (7%)  12 (9%) 25 (6%) 15 (7%) 
     College  233 (26%)  8 (22%) 30 (25%) 195 (26%)  41 (30%) 101 (24%) 53 (26%) 
     University  308 (34%)  18 (49%) 40 (42%) 240 (32%)  41 (30%) 141 (34%) 58 (29%) 
Annual household income, n 
(%)1 
          
     <$10,000  11 of 668 (2%)  2 of 29 (7%) 1 of 96 (1%) 8 of 543 (1%)  1 of 96 (1%) 4 of 296 (1%) 3 of 151 (2%) 
     $10,000 to $20,000  26 of 668 (4%)  2 of 29 (7%) 3 of 96 (3%) 21 of 543 (4%)  3 of 96 (3%) 11 of 296 (4%) 7 of 151 (5%) 
     $20,000 to $30,000  35 of 668 (5%)  3 of 29 (10%) 7 of 96 (7%) 25 of 543 (5%)  6 of 96 (6%) 11 of 296 (94%) 8 of 151 (5%) 
     $30,000 to $40,000  46 of 668 (7%)  3 of 29 (10%) 2 of 96 (2%) 41 of 543 (8%)  11 of 96 (11%) 21 of 296 (7%) 9 of 151 (6%) 
     $40,000 to $50,000  42 of 668 (6%)  3 of 29 (10%) 2 of 96 (2%) 37 of 543 (7%)  7 of 96 (7%) 20 of 296 (7%) 10 of 151 (7%) 
     $50,000 to $60,000  40 of 668 (6%)  2 of 29 (7%) 8 of 96 (8%) 30 of 543 (6%)  6 of 96 (6%) 16 of 296 (5%) 8 of 151 (5.3%) 
     $60,000 to $70,000  65 of 668 (10%)  2 of 29 (7%) 6 of 96 (6%) 57 of 543 (11%)  12 of 96 (13%) 31 of 296 (10%) 14 of 151 (9%) 
     $70,000 to $80,000  60 of 668 (9%)  1 of 29 (3%) 15 of 96 (16%) 44 of 543 (8%)  6 of 96 (6%) 26 of 296 (9%) 12 of 151 (8%) 
     $80,000 to $90,000  57 of 668 (9%)  2 of 29 (7%) 6 of 96 (6%) 49 of 543 (9%)  8 of 96 (8%) 29 of 296 (10%) 12 of 151 (8%) 
     $90,000 to $100,000  51 of 668 (8%)  1 of 29 (3%) 5 of 96 (5%) 45 of 543 (8%)  8 of 96 (8%) 24 of 296 (8%) 13 of 151 (9%) 
     >$100,000  235 of 668 (35%)  8 of 29 (28%) 41 of 96 (43%) 186 of 543 (34%)  28 of 96 (29%) 103 of 296 (35%) 55 of 151 (36%) 
           
Annual household income,  
median (IQR), (CAD 2016)3 
 $81,659  
(48,449-114,730) 
 $62,271  
(36,253- 105,937) 
$91,598  
(63,127-114,730) 
$81,376  
(47,867-114,631) 
 $76,607  
(47,580-113,047) 
$82,608  
(50,923-114,532) 
$85,203  
(47,688-114,730) 
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Variable 
   Donation-type group (N = 912) 
 Relationship-type group 
(N = 757)2 
 All donors 
(N = 912) 
 Non-directed donors 
(n = 37) 
Kidney paired 
donors 
(n = 118) 
All other donors 
 (n = 757) 
 Spousal donors 
(n = 138) 
Closely related 
donors 
(n = 417) 
Unrelated donors 
(n = 202) 
Province of transplant centre, 
n (%) 
          
Alberta  132 (15%)  5 (14%) 14 (12%) 115 (15%)  10 (7%) 70 (17%) 35 (17%) 
British Columbia  274 (30%)  13 (35%) 47 (48%) 204 (27%)  41 (30%) 106 (25%) 57 (28%) 
Manitoba  37 (4%)  0 (0%) 2 (2%) 35 (5%)  2 (1%) 27 (6%) 6 (3%) 
Nova Scotia  42 (5%)  1 (3%) 4 (3%) 37 (5%)  4 (3%) 27 (6%) 6 (3%) 
Ontario  379 (42%)  18 (48%) 38 (32%) 323 (43%)  67 (49%) 164 (39%) 92 (46%) 
Quebec 
 
 46 (5%)  0 (0%) 3 (3%) 43 (6%)  14 (10%) 23 (6%) 6 (3%) 
Relationship to recipient, n 
(%) 
          
Sibling  211 (23%)  0 (0%) 0 (0%) 211 (28%)  0 (0%) 211 (51%) 0 (0%) 
Parent  128 (14%)  0 (0%) 0 (0%) 128 (17%)  0 (0%) 128 (31%) 0 (0%) 
Son/daughter  78 (9%)  0 (0%) 0 (0%) 78 (10%)  0 (0%) 78 (19%) 0 (0%) 
Spouse/partner  138 (15%)  0 (0%) 0 (0%) 138 (18%)  138 (100%) 0 (0%) 0 (0%) 
Friend  104 (11%)  0 (0%) 0 (0%) 104 (14%)  0 (0%) 0 (0%) 104 (51%) 
Don’t know recipient  155 (17%)  37 (100%) 118 (100%) 0 (%)  0 (0%) 0 (0%) 0 (0%) 
Other  98 (11%)  0 (0%) 0 (0%) 98 (13%)  0 (0%) 0 (0%) 98 (49%) 
 1 Annual household income was an optional response and thus only available for 668 donors. Responses for all other variables were complete. 
2 Among donors not participating in non-directed or kidney paired donations. 
3 Median (IQR) income available from all donors: derived from mid-point of imputed categorical values inflated to 2016 Canadian dollars (i.e. $15,000 when the donor reported 
an income level of $10,000 to $20,000). An income of $110,000 was used for donors reporting household incomes >$100,000, and $5000 was used for donors reporting 
<$10,000. 
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5.1.2 Costs Incurred and Resources Consumed  
All costs are reported in 2016 Canadian dollars (CAD) as means (standard deviation) 
and medians (25th percentile-75th percentile). 
For all donors, the mean total cost (sum of direct and indirect costs) was $4790 (6122), 
and median total cost was $2616 (1073-6120). The mean direct cost incurred (from the 
beginning of donor evaluation up to three months post-donation) was $2110 (2505), and 
the median direct cost was $1302 (581-2674) (Table 5). The mean indirect cost incurred 
by all donors was $2679 (5478), and median indirect cost was $22 (0-2770).  
 
Table 5. Direct, indirect, and total incurred costs 
(CAD), for all donors, including those incurring no 
expenses (n = 912). 
Cost type 
Costs incurred, all donors (CAD) 
Mean (SD) Median (25th-75th percentile) 
Direct 2110 (2505) 1302 (581-2674) 
Indirect 2679 (5478) 22 (0-2770) 
Total 4790 (6122) 2616 (1073-6120) 
 
Approximately 23% of living kidney donors incurred less than $1000 in total costs 
throughout the donation process (Figure 4). However, about 28% of donors experienced 
costs >$5500, which is the most common maximum amount of reimbursement offered 
by provincial programs. Beyond this, 13.3% of donors experienced total costs over 
$10,000 and 8.6% of donors incurred total costs greater than 25% of their household 
income. 
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 Direct Costs and Resources  
Among donors incurring direct costs, the greatest cost was for ground travel, followed 
by non-hospital paid accommodation (Table 6). Incurred expenses most frequently 
reported by donors were for ground travel (90%), parking (90%), and medications 
(77%).  
Donors reported a median of 10 return trips to transplant centres to see health 
professionals. Air travel was reported by 21% of donors with a median of 1 return flight. 
Among donors reporting air travel, 71% had friends and/or family who incurred flight 
costs while accompanying them throughout the donation process. Approximately 45% 
of donors reported costs for non-hospital paid accommodation, and stayed a median of 4 
Figure 4. Relative frequency of total costs incurred by living kidney donors (n = 912). 
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nights. Additionally, 38% of donors reported that friends and/or family incurred 
accommodation costs while accompanying them during their kidney donation. 
Among those reporting the outcome or consuming the resource, the mean costs per 
donor were $1113 for ground travel, $1063 for non-hospital paid accommodation, $781 
for accommodation with family or friends, $294 for hospital accommodation, $138 for 
parking, and $69 for pain medications or antibiotics post-surgery. For donors who flew 
during the evaluation and donation process, the average cost of air travel was $639. 
For all donors (including those reporting no out-of-pocket expenses for any cost 
category), the average costs per donor were $999 for ground travel, $474 for non-
hospital paid accommodation, $203 for accommodation with family or friends, $137 for 
air travel, $133 for hospital accommodation, $122 for parking, and $43 for medications. 
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Table 6. Direct costs (2016 CAD) incurred and resource use from 3-month economic assessment. 
Cost category Description 
Donors 
reporting 
resource, 
 n (%)2 
Resource use3 Costs
 for donors reporting expense 
(CAD)  
Costs for all donors, n = 912 
(CAD) 
Units Median (IQR) Average (SD) 
Median  
(IQR) Average (SD) Median (IQR) 
Travel Ground travel 818 (90%) # Return trips 10 (7-15) 1113 (1623) 513 (194-1261) 999 (1574) 407 (129-1146) 
Air travel 195 (21%) # Return trips 1 (1-2) 639 (462) 561 (327-757) 137 (338) 0 (0-0) 
Parking1 824 (90%) # Days of paid parking 7 (4-11) 138 (292) 104 (55-165) 122 (278) 90 (42-158) 
Accommodation Family and 
friends1 287 (31%) # Nights 6 (3-12) 781 (1497) 319 (160-774) 203 (835) 0 (0-42) 
Non-hospital 
paid 407 (45%) # Nights 4 (2-8) 1063 (1711) 618 (227-1249) 474 (1258) 0 (0-540) 
Hospital1 414 (45%) # Nights 4 (3-5) 294 (522) 105 (48-341) 133 (381) 0 (0-101) 
Medication Post-donation 
pain medication 
or antibiotics 
after hospital 
discharge1 
700 (77%) Drugs taken (yes/no) n/a 69 (211) 33 (21-63) 43 (170) 16 (0-45) 
1 Self-reported costs (not micro- costed). 
2 Number of donors reporting resource use (even if no out-of-pocket expenses were incurred). 
3 In donors reporting the outcome; medications provided in hospital are covered through universal health care. Some outpatient drugs are also covered through universal healthcare 
plans for segments of the population (e.g. in the province of Ontario, Canada those 65 years and older have universal drug benefits).
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 Indirect Costs and Resources 
Across all donors, 707 (78%) reported that they were unable to go to work for a median 
of 35 days following surgery (Table 7). Lost income for donors who were unable to 
work, including time off with or without loss of pay (i.e. use of sick days or vacation 
time), was an average of $8702 per donor. Moreover, 39% of all donors reported that 
time away from work resulted in lost wages, with a median of 20 days unpaid. Among 
donors who reported unpaid time off work, the average loss of wages was $6322 per 
donor.  
Across all donors, 740 (81%) were unable to perform household activities for a median of 
15 days post-surgery, and 516 (57%) were unable to care for dependents for a median of 
14 days post-surgery. Among donors reporting productivity losses, household and 
dependent out-of-pocket costs incurred were an average of $736 and $977 per donor, 
respectively.  
For all 912 donors (including those reporting no productivity losses), the mean costs per 
donor were $6762 for inability to work, $2470 for lost wages, $112 for lost household 
productivity, and $97 for caring for dependents. 
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 Table 7.  Indirect costs (2016 CAD) incurred and resource use, up to 3-month economic assessment. 
Cost category Description 
Donors 
reporting 
resource, 
n (%)4 
Number of days5 Costs
 for donors reporting expense 
(CAD) 
Costs for all donors, n = 912 
(CAD) 
Median (IQR) Average (SD) Median (IQR) Average (SD) Median (IQR) 
Lost income* Unable to work if 
employed1 707 (78%) 35 (15-60) 8702 (6709) 7488 (3391-12,447) 6762 (6935)  5572 (597-11,119) 
Unpaid time off 
work2 356 (39%) 20 (9-42) 6322 (6779) 4055 (1881-8956) 2470 (5239) 0 (0-2579) 
Lost productivity Unable to perform 
household activities3 740 (81%) 15 (10-30)  736 (2881) 320 (204-531) 112 (1149) 0 (0-0) 
Unable to care for 
dependants3 516 (57%) 14 (7-25) 977 (2159) 344 (172-657) 97 (740) 0 (0-0) 
     * Time valued at provincial average wage rate: assuming 8-hour work day 
     1 With or without loss of pay. 
     2 Included in calculation of total cost. 
     3 Self-reported costs (not micro-costed).  
     4 Number of donors reporting resource use (even if no out-of-pocket expenses were incurred). 
     5 In donors reporting the outcome.  
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 Univariate Analysis of Costs 
This section describes differences in direct, indirect, and total costs borne by donors 
contrasting donation-type and relationship-type groups within the Canadian living kidney 
donor population. Costs are reported in 2016 Canadian dollars as means and mean 
differences with 95% confidence intervals. 
5.2.1 Costs Incurred by Donation-Type Groups 
For the period beginning with donor evaluation and ending at 3 months post-surgery, 
non-directed donors (n = 37) incurred average direct, indirect, and total costs of $2095, 
$2550, and $4645, respectively (Table 8). Kidney paired donors (n = 118) incurred 
average direct, indirect, and total costs of $2394, $2045, and $4439, respectively. The 
mean direct, indirect, and total expenses incurred by all other donors (n = 757) were 
$2067, $2785, and $4852, respectively.  
There were no significant differences in the mean direct, indirect, and total costs incurred 
by either non-directed donors or kidney paired donors, as compared to all other donors. 
The mean differences in total costs experienced by non-directed donors and kidney 
paired donors relative to the total costs incurred by all other donors were -$207 (-2167 to 
1753) and -$413 (-1537 to 712), respectively (Figure 5). For non-directed donors, the 
mean differences in direct and indirect costs incurred compared to all other donors were 
$28 (804 to 859) and -$235 (-1482 to 1951), respectively.  For kidney paired donors, the 
mean differences in direct and indirect costs relative to all other donors were $327 (-237 
to 890) and -$740 (-1595 to 116), respectively.  
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Table 8. Unadjusted direct, indirect, and total costs (2016 CAD) incurred by living kidney donors, by donation-type group (n = 912). 
 All Other Donors Non-Directed Donors Kidney Paired Donors  All Other Donors 
Non-Directed 
Donors 
Kidney 
Paired 
Donors 
Cost type Mean
 
(95% CI)1 
MD 
(95% CI)2 
Mean 
(95% CI)1 
MD 
(95% CI)2 
Mean  
(95% CI)1 
MD 
(95% CI)2  
Median 
(IQR) 
Median 
(IQR) 
Median 
(IQR) 
Direct 2067 (1879 to 2255) ref 
2095 
(1266 to 2923) 
28 
(-804 to 859) 
2394 
(2040 to 2748) 
327 
(-237 to 890)  
1221 
(551-2550) 
1984 
(702-2639) 
2060 
(1022-3263) 
Indirect 2785 (2372 to 3197) ref 
2550 
(810 to 4290) 
-235 
(-1482 to 1951) 
2045 
(1366 to 2724) 
-740 
(-1595 to 116)  
40 
(0-2832) 
104 
(0-2499) 
3 
(0-2359) 
Total 4852 (4396 to 5307) ref 
4645 
(2694 to 6595) 
-207 
(-2167 to 1753) 
4439 
(3607 to 5271) 
-413 
(-1537 to 712)  
2520 
(1016-6230) 
2695 
(1191-4477) 
2970 
(1639-5933) 
1 Bootstrapped mean and 95% confidence interval. 
     2 MD = mean difference, as marginal effect from univariate generalized linear model. 
Figure 5. Mean direct and indirect costs by cost category and donation-type group. 
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5.2.2  Costs Incurred by Relationship-Type Groups 
As of three months post-donation, spousal donors (n = 138) incurred average direct, 
indirect, and total costs of $2379, $2947, and $5326, respectively (Table 9). Closely 
related donors (n = 417) incurred average direct, indirect, and total costs of $1984, 
$2963, and $4947, respectively. And finally, the mean direct, indirect, and total expenses 
incurred by unrelated donors (n = 202) were $2026, $2305, and $4330, respectively.  
There were no significant differences in the mean direct, indirect, and total costs incurred 
by either closely related donors or unrelated donors, as compared to spousal donors. For 
closely related donors, the mean difference in total costs relative to spousal donors was -
$379 (-1693 to 935). For unrelated donors, the mean difference in total costs compared to 
spousal donors was -$996 (-2393 to 402). 
The mean differences in direct costs incurred by closely related donors and unrelated 
donors compared to those incurred by spousal donors were -$395 (-943 to 153) and -
$353 (-955 to 249), respectively (Figure 6). Mean differences in indirect costs compared 
to spousal donors were $16 (-1146 to 1178) for closely related donors, and -$642 (-1842 
to 557) for unrelated donors.  
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Table 9. Unadjusted direct, indirect, and total costs (2016 CAD) incurred by living kidney donors, by relationship-type group (n = 757)3. 
 
Spousal Donors Closely Related Donors Unrelated Donors  Spousal Donors 
Closely 
Related 
Donors 
Unrelated 
Donors 
Cost type Mean
 
(95% CI)1 
MD 
(95% CI)2 
Mean 
(95% CI)1 
MD 
(95% CI)2 
Mean  
(95% CI)1 
MD 
(95% CI)2  
Median 
(IQR) 
Median 
 (IQR) 
Median 
(IQR) 
Direct 2379 (1815 to 2943) ref 
1984 
(1750 to 2217) 
-395 
(-943 to 153) 
2026 
(1670 to 2381) 
-353 
(-955 to 249)  
1289 
(562-2471) 
1193 
(554-2574) 
1214 
(509-2473) 
Indirect 2947 (1751 to 4143) ref 
2963 
(2423 to 3503) 
16 
(-1146 to 1178) 
2305 
(1669 to 2941) 
-642 
(-1842 to 557)  
139 
(0-3034) 
25 
(0-2931) 
15 
(0-2668) 
Total 5326 (3985 to 6667) ref 
4947 
(4350 to 5544) 
-379 
(-1693 to 935) 
4330 
(3593 to 5068) 
-996 
(-2393 to 402)  
2190 
(1097-6480) 
2629 
(963-6159) 
2493 
(1043-6204) 
1 Bootstrapped mean and 95% confidence interval. 
2 MD = mean difference, as marginal effect from univariate generalized linear model. 
3 Among donors not participating in non-directed or kidney paired donations. 
 
 
 
 
Figure 6. Mean direct and indirect costs by cost category and relationship-type group. 
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 Multivariable Analyses of Costs  
This section describes the adjusted average marginal effects of donation-type, 
relationship-type, and demographic characteristics on mean direct, indirect, and total 
costs incurred by living kidney donors during the donation process. Marginal effects are 
reported as mean differences and 95% confidence intervals in costs (in 2016 Canadian 
dollars) compared to a reference category. Average marginal costs are adjusted for age, 
sex, income level, Clavien-Dindo grade, and transplant centre. 
5.3.1 Primary Analysis 
In adjusted analyses, the mean direct costs experienced by either non-directed donors or 
kidney paired donors were not significantly different compared to the direct costs 
incurred by all other donors (Table 10). The mean differences in direct costs borne by 
non-directed donors and kidney paired donors relative to all other donors were $119 (-
644 to 882) and $321 (-54 to 695), respectively. Adjusted mean indirect and total costs 
incurred by either non-directed donors or kidney paired donors were not significantly 
different than those experienced by all other donors. Mean differences in indirect and 
total costs, compared to all other donors, were respectively -$351 (-1742 to 1040) and -
$434 (-1632 to 765) for non-directed donors. For kidney paired donors, mean differences 
in indirect and total costs relative to all other donors were -$252 (-958 to 453) and $120 
(-786 to 1026), respectively.  
The mean indirect out-of-pocket expenses incurred by spousal donors were not 
significantly different compared to either closely related donors or unrelated donors. In 
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adjusted analyses, mean differences in indirect costs experienced by closely related 
donors and unrelated donors relative to spousal donors were $50 (-1243 to 1343) and -
$856 (-1834 to 122), respectively. Mean differences in direct and total costs incurred by 
closely related donors and unrelated donors compared to the referent group of spousal 
donors were not significant. Mean differences in direct and total costs, compared to 
spousal donors, were respectively -$235 (-660 to 190) and -$332 (-1565 to 901) for 
closely related donors. For unrelated donors, mean differences in direct and total costs 
relative to spousal donors were -$122 (-851 to 606) and -$1034 (-2136 to 67), 
respectively. 
5.3.2 Secondary Analyses 
In adjusted analyses, donors who lived further from the transplant centre in which they 
were evaluated (≥100 km) experienced significantly higher direct and total costs, as 
compared to donors who lived closer (<100 km); mean differences in indirect costs 
between these two groups was non-significant.  
Though older and younger donors did not significantly differ in total costs incurred, there 
were significant differences in indirect and direct costs between the groups (Figure 7). In 
multivariable analyses, donors in the 35 to 54 year-old and 55+ year-old age groups 
experienced significantly higher mean direct costs compared to the referent 18 to 34 
year-old donor group (Table 10). Donors 55 years of age and older faced significantly 
lower mean indirect costs compared to 18 to 34 year-old donors (mean difference = -
$1543 [-2622 to -465], p = 0.005). The mean differences in total costs compared to 18 to 
24 year-old donors were not significant for any age group.  
50 
 
 
 
There was a significant trend of an increasing number of trips to transplant centres for 
evaluation (p = 0.03) and higher travel costs (p < 0.001), as well as greater number of 
nights in paid accommodation (p <0.001) and higher accommodation costs across older 
age groups (p = 0.004). Conversely, the number of days off work (p <0.001) and lost 
wages significantly decreased across older age groups (p <0.001). 
 
Figure 7. The mean direct and indirect costs incurred by donors by age category. 
 
In adjusted analyses, the mean costs incurred by male donors and female donors did not 
differ significantly; mean differences in direct and indirect costs for female donors 
relative to male donors were -$75 (-381 to 231) and -$506 (-152 to 1164), respectively. 
The indirect and total costs experienced by employed donors were significantly higher 
than both unemployed donors and retired donors. Mean differences in indirect and total 
costs incurred, compared to employed donors, were respectively -$1838 (-2580 to -1096, 
p < 0.001) and -$2433 (-3369 to -1497, p <0.001) for unemployed donors, and -$2614 (-
3214 to -2014, p < 0.001) and -$2482 (-3262 to -1702, p < 0.001) for retired donors. 
Compared to donor households making less than $20,000 in annual income, the average 
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marginal effect of household income (across all levels of income ≥$20,000) on donor 
direct, indirect, and total costs was non-significant.  
Compared to those donating in Ontario, donors who donated their kidneys in Alberta and 
Manitoba experienced significantly lower mean direct costs. Mean differences in direct 
expenses compared to Ontarian donors were -$594 (-1001 to -187, p = 0.004) in Alberta 
and -$1032 (-1711 to -354, p = 0.003) in Manitoba. Indirect and total costs of donating in 
any province did not differ significantly compared to donating in Ontario. 
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Table 10. Adjusted1 average marginal effects of demographic variables on direct, indirect, and total 
costs (2016 CAD) incurred by living kidney donors (n = 912). 
 
Variable 
Direct costs (CAD) Indirect costs (CAD) Total costs (CAD) 
Marginal effect 
(95% CI) p 
Marginal effect 
(95% CI) p 
Marginal effect 
(95% CI) p 
Donation-type       
All other donors ref  ref  ref  
Non-directed donors 119 (-644 to 882) 0.76 -351 (-1742 to 1040) 0.62 -434 (-1632 to 765) 0.48 
Kidney paired donors 321 (-54 to 695) 0.09 -252 (-958 to 453) 0.48 120 (-786 to 1026) 0.80 
Relationship-type2       
Spousal donors ref  ref  ref  
Closely related donors -235 (-660 to 190) 0.28 50 (-1243 to 1343) 0.94 -332 (-1565 to 901) 0.60 
Unrelated donors -122 (-851 to 606) 0.74 -856 (-1834 to 122) 0.09 -1034 (-2136 to 67) 0.07 
Distance from centre       
<100 km ref  ref  ref  
 ≥100 km 2645 (2229 to 3060) <0.001 -235 (-896 to 425) 0.49 2583 (1813 to 3353) <0.001 
Sex       
Male ref  ref  ref  
Female -75 (-381 to 231) 0.63 -506 (-152 to 1164) 0.13 -566 (-10 to 1142) 0.054 
Age (years)       
    <35 ref  ref  ref  
    35 to 54 570 (115 to 1025) 0.01 -762 (-1939 to 415) 0.20 -70 (-1392 to 1252) 0.92 
    55+ 712 (141 to 1283) 0.01 -1543 (-2622 to -465) 0.005 -597 (-1786 to 593) 0.33 
Race       
White ref  ref  ref  
Non-White -234 (-673 to 205) 0.30 -390 (-1553 to 772) 0.51 -403 (-1641 to 835) 0.52 
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Variable 
Direct costs (CAD) Indirect costs (CAD) Total costs (CAD) 
Marginal effect 
(95% CI) p 
Marginal effect 
(95% CI) p 
Marginal effect 
(95% CI) p 
Income (CAD)       
 <$20,000 ref  ref  ref  
$20,000 to $40,000 759 (-144 to 1663) 0.10 617 (-1990 to 3224) 0.64 1569 (-1099 to 4237) 0.25 
$40,000 to $60,000 742 (-129 to 1613) 0.09 -915 (-3070 to 1241) 0.40 14 (-2217 to 2244) 0.99 
$60,000 to $80,000 752 (-113 to 1618) 0.09 -585 (-3048 to 1877) 0.64 329 (-2038 to 2697) 0.79 
$80,000 to $100,000 319 (-502 to 1141) 0.44 -1544 (-4050 to 961) 0.23 -993 (-3625 to 1639) 0.46 
>$100,000 346 (-481 to 1173) 0.41 -1894 (-4011 to 223) 0.08 -1391 (-3451 to 669) 0.18 
Employment status       
Employed ref  ref  ref  
Unemployed -551 (-1114 to 11) 0.06 -1838 (-2580 to -1096) <0.001 -2433 (-3369 to -1497) <0.001 
Retired -190 (-542 to 162) 0.29 -2614 (-3214 to -2014) <0.001 -2482 (-3262 to -1702) <0.001 
Other 112 (-706 to 931) 0.79 -204 (-2054 to 1646) 0.83 -218 (-2178 to 1742) 0.83 
Province of transplant 
centre       
Ontario ref  ref  ref  
Alberta -594 (-1001 to -187) 0.004 764 (-586 to 2114) 0.27 212 (-1086 to 1510) 0.75 
British Columbia 77 (-317 to 471) 0.70 -45 (-911 to 820) 0.92 177 (-747 to 1100) 0.71 
Manitoba -1032 (-1711 to -354) 0.003 480 (-1652 to 2612) 0.66 -355 (-2407 to 1698) 0.74 
Nova Scotia 312 (-454 to 1078) 0.42 -405 (-1997 to 1187) 0.62 0 (-1740 to 1739) 1.00 
Quebec 106 (-743 to 956) 0.81 375 (-1503 to 2253) 0.70 421 (-1625 to 2466) 0.69 
1 Adjusted for age, sex, income, Clavien-Dindo grade, and transplant centre. 
2 Among donors not participating in non-directed or kidney paired donations (n = 757). 
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Chapter 6 
6 Discussion and Conclusion 
The following sections will discuss the findings of this work in the context of the 
research questions and hypotheses, draw comparisons to the existing body of evidence, 
evaluate the broader societal implications of the results, assess the work’s strengths and 
weaknesses, and project the necessary next steps and future directions within the field of 
living kidney donor outcomes. 
 Overview 
An overarching goal of this work was to comprehensively characterize the resources and 
costs of living kidney donation at a granular level. To our knowledge, our study is the 
largest of its kind to prospectively capture the economic outcomes of donors and the first 
to evaluate whether some types/groups of donors experience higher costs than others. 
Furthermore, our inclusion of kidney paired donors, who face unique donation 
circumstances, and a larger sample size, increase the generalizability and accuracy of our 
estimates.  
Given the consensus within the transplant community and among the general public that 
living kidney donors should not be disadvantaged by their gift of life, removing 
significant financial hardship is paramount to upholding a just healthcare 
system.102,104,178,179 Our finding that donors experience an average total cost of $4790 
(median = $2616) throughout the donation process adds to the growing body of evidence 
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that living kidney donors experience substantial financial losses due to donation. We 
anticipated that our large sample size and a comprehensive micro-costing approach 
would offer a more accurate estimate of donor expenses, and more specifically, that our 
estimates would exceed those within the existing literature. Our cohort of 912 living 
kidney donors incurred an average direct cost of $2110 during donation, higher than 
estimates of $1780 (2008 CAD) and $1157 (USD) from previous studies.1,98 We found 
that 18% and 30% of donors experience costs exceeding $8000 and $5000, respectively: 
greater than estimates previously reported by Klarenbach et al. (15% of donors with 
>$8000 total costs; 2008 CAD) and Rodrigue et al. (20% of donors with >$5000 total 
costs; USD).1,98 Beyond this, 13.3% of donors experienced costs in excess of $10,000 and 
8.6% of donors incurred costs >25% of their annual household income. Importantly, 28% 
of donors incurred total costs exceeding the upper limit of reimbursement offered in 
Canada, leaving them with little recourse to shoulder the additional financial burden. 
With growing transplant waitlists and stagnating rates of donation, the high costs we 
observed demonstrate a need to limit the impact of financial disincentives on living 
kidney donation.9 
To our knowledge, our study is the first to explore important potential donor subgroup 
differences. The 2017 Kidney Disease: Improving Global Outcomes (KDIGO) Clinical 
Practice Guideline on the Evaluation and Care of Living Kidney Donors highlighted the 
need to study approaches to reduce financial disincentives to living donation, “with 
particular attention to impact on current disparities in living donor kidney 
transplantation”.44 Dew et al. noted gaps in the available evidence regarding the financial 
outcomes of donors related to their recipients compared to unrelated donors.180 Our 
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comparisons of costs incurred between donation-type and relationship-type groups 
revealed that there are no meaningful differences in the economic outcomes of these 
donors. The finding is reassuring given the increasingly critical role kidney paired 
donation has assumed in offering life-extending treatment to patients with end-stage 
kidney disease. Kidney paired donation has been responsible for over 500 transplants in 
Canada since 2009, at a time during which rates of donation have plateaued, 
demonstrating the vital role these donors play in meeting the growing demand for 
kidneys. The finding that Canadian kidney paired donors do not face higher costs than 
other donors is encouraging for the continued success of the program, particularly in the 
potential inclusion of directed compatible donor-recipient pairs.110 Spousal donors are 
responsible for about 15% of transplants in Canada, and given the potential additional 
financial burden of both the donor and recipient undergoing major surgery, it is 
encouraging that this sizeable group of donors does not shoulder significantly greater 
indirect and total costs related to loss of income or home productivity, as previously 
hypothesized. The findings of our study help contribute to the body of evidence 
supporting improved management of the financial consequences of living donation and 
the continued growth of kidney paired donation in Canada. 
In our secondary analyses, we explored associations between demographic characteristics 
and incurred costs, the first time this analysis has been undertaken within a Canadian 
group of donors. Our findings that living >100 km from transplant evaluation centre and 
being employed are significantly associated with incurred total costs may guide informed 
consent practices and prepare donors for the burden of costs they may encounter during 
the evaluation and donation process. Rodrigue et al. also found that longer distance to 
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transplant program was significantly correlated to financial loss.98 Our results lend 
support to previous work in Australia describing distinct differences between the 
financial outcomes of donors living in urban centres as compared to rural donors; the 
study’s authors argue that these differences in costs reflect a “rural disadvantage”.181 
Though total costs did not vary across age groups, the drivers of costs differed between 
younger and older living kidney donors. Our finding that older donors incurred higher 
direct costs possibly reflects additional testing and evaluation in this population due to 
comorbidities, and indeed older donors did take more trips to their transplant evaluation 
centre and incurred higher travel and accommodation costs. Younger donors, on the other 
hand, encountered higher indirect costs than older donors, which reflects differences in 
employment and increased number of unpaid days off work and lost wages for younger 
donors. Recognizing these important differences in direct and indirect costs incurred by 
donors will enable transplant programs to better prepare donor candidates for the 
financial losses they may encounter during donation. 
 Implications 
In recent years, the rate of living kidney donation in Canada has plateaued despite an ever 
increasing demand.9 In the U.S. these rates have decreased, a finding that has been linked 
to recent economic decline, and beyond this, evidence suggests that the disparity in rates 
of living donation between low-income and high-income groups has widened over this 
same period.116,119 A survey of transplant candidates revealed substantial concern and 
reluctance about living kidney donation due to the financial consequences encountered by 
donors.182 
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A report from Israel demonstrated that the implementation of legislation which reduced 
financial disincentives substantially increased the rates of living kidney donation.183 
There is longstanding consensus within the transplant community that donating one’s 
kidney should be a financially neutral act.104 A report by Hays et al. offered an 
operational definition and a framework for financial neutrality that included medical 
costs, travel costs, accommodation costs, and lost wages.20 The authors further argued 
that financial costs affect donor decision making and that achieving financial neutrality 
would serve to increase living donation rates.20 
A consensus conference on best practices in living kidney donation developed a set of 
recommendations on reducing financial barriers to donation.184 In their report, the authors 
argue for a standardized system of reimbursement, legislation that protects employed 
donors, development of a financial toolkit , and collection of granular data on costs 
incurred by donors.184 Rudow et al. reiterated these practical recommendations by 
arguing that cost-effective reimbursement is possible by leveraging the cost savings 
associated with living donation.185 
Our findings work to advance several of these recommendations, particularly in offering 
the granular cost data that allows for the implementation of evidence-based patient 
advocacy and education initiatives. This work offers the most comprehensive and 
granular understanding of the costs incurred by donors, and the demographic factors 
associated with these costs, to date. Our findings support the development of equation 
models (to estimate the costs donor candidates may encounter), and a financial toolkit 
(which may be used by transplant programs to communicate the financial risks of 
donation and refer donors to appropriate resources and services): addressing key evidence 
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gaps behind consensus recommendations offered by Tushla et al. in their report.184 
Beyond this, understanding and quantifying the economic outcomes of living donation is 
paramount to guiding donor informed consent. 
Rudow et al. argue that expansions of living kidney donation must be implemented with 
knowledge of the risks involved; our finding that kidney paired donors do not face 
financial disadvantages compared to other donors ensures that this group of Canadian 
donors is protected.185 
There is substantial variation in the restrictions and upper limits to reimbursement offered 
by provincial programs across Canada. The comprehensive understanding of these costs 
by type and magnitude will inform and guide policy governing reimbursement. With 28% 
of donors encountering costs in excess of the maximum amount offered by most 
programs, it is time to consider a national and comprehensive reimbursement strategy in 
Canada. 
 Strengths  
A major strength of this report is the multi-centre prospective cohort study design, with 
90% complete follow-up and rigourous statistical methods which accounted for any 
missing data (a modern defensible approach to imputation). The statistical analyses were 
done with special attention paid the characteristically right-skewed nature of cost data, 
and the primary comparisons related to donor relationship type and donation-type were 
prespecified to avoid inflating type 1 errors due to multiple testing. Our study captured 
the outcomes on 37% of living kidney donors who completed their donation within 
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Canada during our recruitment window (from 2009 to 2014). By collecting data for 912 
donors across 12 transplant centres coast-to-coast, we circumvent the major criticisms of 
previous work for sampling a small, geographically limited, and homogenous group of 
donors that is unrepresentative of the larger population.99  
This group of 912 donors represents a sample size over five times larger than the next 
leading study in its field, allowing for assessment of important subgroup differences in 
financial outcomes. Our sample of donors is the first to include donors participating in 
kidney paired donation, a program which began in 2009 in Canada and for which there is 
a paucity of outcome data in the literature. 
Our pre-specified study protocol and cost-capturing instruments were informed by a pilot 
study, allowing for granular, comprehensive, and complete data collection.1 We achieved 
90% follow-up for the 3-month economics assessment, and our group of non-responders 
demographically corresponds to non-responders in previous reports: younger, non-white, 
un-married, and unemployed.100  
 Limitations 
Some limitations of this work include the generalizability of the findings to other health 
care systems, potential underestimation of the true cost borne by donors, incomplete 
income data collection, and restricting the scope of cost capturing to living kidney donors 
who completed donation. 
First, as Canada has a single payer universal health care system, these costs may not 
reflect the entire spectrum of costs that may arise in other settings.  For example, medical 
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costs were not considered during data collection, whereas these costs may be substantial 
in non-universal healthcare settings, particularly considering recommendations for long-
term monitoring of living kidney donors for adverse outcomes.186 There is broad 
consensus among transplant professionals that living donors should be provided 
insurance for long-term follow-up of medical issues related to donation.186 
Second, post-hospital discharge prescription drug coverage varies across provinces; some 
donors would qualify for provincial universal outpatient drug coverage. As such, the 
reported medication costs may not reflect the true outpatient prescription drug cost. 
Beyond this, some donors reported that the transplant centre in which they completed 
their evaluation was within a city they reported as an air travel destination. To avoid 
unreasonable cost estimates for these patients, we assumed that their ground travel was 
local (e.g. hotel to hospital), and assumed no ground travel costs. Lastly, a three month 
window for cost collection may not capture expenses incurred by donors encountering 
long-term complications necessitating services such as physiotherapy or extended home 
care. These assumptions serve to underestimate the true direct costs experienced by these 
groups of donors. 
Another limitation was the completeness of income data: reporting of income was 
optional and data was only available for ~73% of donors, and as such, complete-case 
analyses adjusted for income were restricted to this group of donors. We used donor 
postal codes and corresponding dissemination areas (by way of the Postal Code 
Conversion File provided by Statistics Canada) to obtain donor neighbourhood median 
household income and the Canadian Marginalization Index using 2006 census data; we 
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performed sensitivity analyses by adding these variables to our model to impute missing 
donor household income: our primary results did not change.187,188 
Lastly, cost capturing was restricted to only those living kidney donors who completed 
donation. Donor candidates who were evaluated but never donated encounter important 
financial consequences during testing and evaluation (e.g. time away from work for 
testing). 
 Future Directions 
Living kidney donation is practiced under the tenet that potential risks borne by the donor 
are offset by the psychological benefits of altruism.50 With the financial consequences of 
donation comprehensively evaluated, there is a pressing need to characterize the potential 
impact of costs on the psychosocial and quality of life outcomes of donors to determine if 
increased costs undermine this principle. Beyond this, the identification of gaps in 
reimbursement in Canada, through comparisons of costs incurred with reimbursement 
received, is necessary to appreciate donor net financial loss and the additional cost to the 
healthcare system to implement a comprehensive national program. Lastly, 
comprehensive and targeted characterization of both modifiable and non-modifiable 
drivers of costs incurred by donors would allow transplant programs to mitigate these 
financial risks and to better prepare and educate donor candidates they evaluate. 
There is considerable debate within the transplant community on the ethics of 
incentivizing living kidney donation to increase donation rates.102,104,178,189 Proponents of 
incentives argue that current legislation prohibiting compensation for donation are not 
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rooted in evidence and propose that pilot studies are the next critical step to evaluate 
potential compensation of donors.178 On the other hand, critics of incentivizing living 
donation liken the practice to paying for organs, and instead argue for removal of 
disincentives as a priority.104  
 Conclusion 
In this report, we offer compelling evidence that many living kidney donors incur 
considerable financial costs while providing the gift of life to patients with end-stage 
kidney disease. Each living kidney donation saves the health care system about $250,000 
over a five-year period, yet at the same time a substantial number of donors face costs in 
excess of reimbursement limits and are left to cope with significant financial loss. There 
is a pressing need to remove barriers to donation by leveraging these cost savings to 
develop a cost-effective national and comprehensive reimbursement program. Removing 
financial disincentives would not only ensure a just and equitable system, but may serve 
to increase rates of living donation. The results of this work can be used to guide the 
development of policies and programs that safeguard donors from unfair financial risk 
and work to meet the growing demand for kidney transplants. 
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Appendices 
Appendix A: LKD Study protocol approval by The University of Western 
Ontario Research Ethics Board for Health Sciences Research Involving 
Human Subjects 
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Appendix B: The twelve major transplant centres across Canada participating in 
the Living Kidney Donor Study 
 
Table 11. The major transplant centres participating in the LKD Study and their donor 
recruitment numbers. 
 
Study 
Centre ID Kidney Transplant Centre City 
Donors 
Recruited 
001 London Health Sciences Centre London, ON 77 
002 St. Paul’s Hospital Vancouver, BC 180 
003 The Ottawa Hospital Ottawa, ON 91 
005 Queen Elizabeth II Hospital Halifax, NS 27 
006 St.  Michael's Hospital Toronto, ON 74 
007 St. Joseph's Hospital Hamilton, ON 27 
008 Health Sciences Centre Winnipeg, MB 37 
009 University of Alberta Edmonton, AB 90 
017 Toronto General Hospital Toronto, ON 111 
018 Foothills Medical Centre Calgary, AB 45 
019 Vancouver General Hospital Vancouver, BC 94 
020 Montreal General Hospital Montreal, QC 46 
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Appendix C: LKD Study retention flowchart and worksheets for missing 
and late 3 month assessments. 
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Appendix D: Economic case report forms for 3-month and one-year 
assessments 
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Appendix E: Costing rates used in the valuation of resources 
Table 12. 2016 kilometric travel rates for provinces and territories 
Province Kilometric Rate  (2016 CAD/km) 
Newfoundland 0.530 
Prince Edward Island 0.475 
Nova Scotia 0.485 
New Brunswick 0.485 
Quebec 0.495 
Ontario 0.540 
Manitoba 0.470 
Saskatchewan 0.455 
Alberta 0.435 
British Columbia 0.475 
Yukon 0.590 
Northwest Territories 0.580 
Nunavut 0.575 
From: http://www.cra-arc.gc.ca/travelcosts/ 
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Table 13. Individual and average hotel rates with applicable taxes (2016 CAD).a 
 
Surgery 
Hospital City Hotels 
Hotel Cost 
(CAD/night) 
Average 
Hotel Cost 
(CAD/night) 
Foothills 
Medical Centre Calgary, AB 
Hotel Alma 91.84 
109.39 
Ramada Limited 
Calgary Northwest 104.16 
Best Western Village 
Park Inn 132.16 
Hôpital 
Maisonneuve-
Rosemont 
Montreal, QC 
Le Chablis 118.48 
126.37 
Hotel University 
Montreal 140.99 
Days Inn Montreal 
East 119.66 
Health 
Sciences 
Centre 
Winnipeg, MB 
Canad Inns Destination 
Centre – Health 
Sciences Centre 
140.42 
106.20 
Econo Lodge 89.68 
Hotel Royal Plaza 88.50 
Hôtel-Dieu de 
Québec Quebec City, QC 
Fairmont Le Château 
Frontenac 199.42 
148.68 Hôtel de Vieux-
Québec 158.12 
Hotel Champlain 
Vieux-Quebec 88.5 
University 
Hospital London, ON 
Guest House on the 
Mount 66.67 
115.64 The Windermere 
Manor 158.20 
Ivey Spencer 
Leadership Centre 122.04 
 
Montreal 
General 
Hospital 
 
 
Montreal, QC 
Chateau Versailles 
Hotel Montreal 143.35 
133.09 
Le Méridien Versailles 176.53 
Le Saint-Malo Hotel 79.38 
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Hôpital Notre 
Dame Montreal, QC 
Hotel Dorion 73.45 
120.05 
Hotel Chateau de 
L’Argoat 136.25 
Kutuma Hotel & 
Suites 150.46 
The Ottawa 
Hospital Ottawa, ON 
Best Western PLUS 
Ottawa City Centre 151.96 
121.41 Travelodge Ottawa 
West 120.64 
Richmond Plaza Motel 91.64 
QEII Health 
Sciences 
Centre 
 
Halifax, NS 
Atlantica Hotel Halifax 153.27 
175.11 
Courtyard Halifax 
Downtown 209.43 
The Lord Nelson Hotel 
& Suites 162.63 
Royal Victoria 
Hospital Montreal, QC 
Le Chabrol 112.55 
125.58 La Tour Belvedere 99.52 
Residence Inn 
Montreal Westmount 164.68 
St. Joseph’s 
Healthcare 
Hamilton 
Hamilton, ON 
Homewood Suites by 
Hilton 170.63 
158.58 Staybridge Suites 
Hamilton – Downtown 159.33 
Sheraton Hamilton 
Hotel 145.77 
St. Michael's 
Hospital Toronto, ON 
Bond Place Hotel 117.16 
172.07 Chelsea Hotel 183.28 
The Grand Hotel & 
Suites 215.76 
St. Paul's 
Hospital Vancouver, BC 
Ramada Vancouver 
Downtown 103.24 
149.64 Wedgewood Hotel & 
Spa Vancouver 184.44 
The Fairmont Hotel 
Vancouver 161.24 
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Toronto 
General 
Hospital 
Toronto, ON 
DoubleTree by Hilton 
Hotel Toronto 
Downtown 
222.71 
206.09 
Chelsea Hotel 183.28 
BeSixFifty Hotel 212.28 
University of 
Alberta 
Hospital 
Edmonton, AB 
Campus Tower Suite 
Hotel 220.64 
 
207.57 
Varscona Hotel on 
Whyte 184.80 
Mettera Hotel on 
Whyte 217.28 
Vancouver 
General 
Hospital 
Vancouver. BC 
Holiday Inn 
Vancouver – Centre 
(Broadway) 
160.08 
188.31 Granville Island Hotel 287.68 
Executive Hotel 
Vintage Park 
Vancouver 
117.16 
St. Paul’s 
Hospital Saskatoon, SK 
Super 8 Saskatoon  123.20 
160.53 Holiday Inn Saskatoon  152.32 
Hilton Garden Inn  206.08 
  a Discussion of prices in section 4.2.4.3.  
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Table 14. Applicable taxes on accommodations in each province. 
 
Province/City                            Applicable Taxes and Fees 
Alberta = 12% (5% GST + 4% levy + 3% DMF) 
British Columbia   = 16% (5% GST + 8% PST (for accommodation) + 3% DMF)  
Manitoba = 18% (5% GST + 8% PST + 5% DMF) 
Nova Scotia = 17% (15% HST + 2% DMF) 
Saskatchewan = 12% (5% GST + 5% PST + 2% DMF) 
Ontario  
Toronto 16% (13% HST + 3% DMF) 
Ottawa 16% (13% HST + 3% DMF) 
Hamilton 13% (13% HST) 
London 13% (13% HST) 
Quebec  
Montreal = 18.475% (5% GST + 9.975 PST + 3.5% DMF) 
Quebec City = 17.975% (5% GST + 9.975 PST + 3% DMF) 
 
GST = federal goods and services tax, PST = provincial sales tax, HST = harmonized sales tax, DMF = 
tourism levies or destination marketing fees  
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Table 15. Average age-, sex-, and province-specific wage rates (2016 CAD). 
Province1 Sex Age group Average wage rate (2016 CAD) 
Newfoundland and 
Labrador 
Males 
15 to 24 years 14.95 
25 to 54 years 28.95 
55 years and over 26.44 
Females 
15 to 24 years 14.08 
25 to 54 years 24.02 
55 years and over 20.44 
Prince Edward Island 
Males 
15 to 24 years 13.47 
25 to 54 years 23.29 
55 years and over 22.59 
Females 
15 to 24 years 12.92 
25 to 54 years 22.63 
55 years and over 21.32 
Nova Scotia 
Males 
15 to 24 years 13.86 
25 to 54 years 25.53 
55 years and over 25.40 
Females 
15 to 24 years 13.72 
25 to 54 years 23.53 
55 years and over 22.62 
New Brunswick 
Males 
15 to 24 years 13.50 
25 to 54 years 24.58 
55 years and over 23.46 
Females 
15 to 24 years 13.27 
25 to 54 years 22.88 
55 years and over 19.99 
Quebec 
Males 
15 to 24 years 14.95 
25 to 54 years 27.72 
55 years and over 26.49 
Females 
15 to 24 years 13.89 
25 to 54 years 24.97 
55 years and over 22.18 
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Ontario 
Males 
15 to 24 years 14.78 
25 to 54 years 30.28 
55 years and over 30.29 
Females 
15 to 24 years 13.91 
25 to 54 years 26.37 
55 years and over 26.00 
Manitoba 
Males 
15 to 24 years 14.94 
25 to 54 years 26.44 
55 years and over 26.91 
Females 
15 to 24 years 14.15 
25 to 54 years 23.86 
55 years and over 24.84 
Saskatchewan 
Males 
15 to 24 years 17.61 
25 to 54 years 30.91 
55 years and over 31.85 
Females 
15 to 24 years 15.76 
25 to 54 years 26.40 
55 years and over 26.34 
Alberta 
Males 
15 to 24 years 18.08 
25 to 54 years 35.14 
55 years and over 34.93 
Females 
15 to 24 years 16.32 
25 to 54 years 28.17 
55 years and over 29.12 
British Columbia 
Males 
15 to 24 years 15.81 
25 to 54 years 30.00 
55 years and over 29.30 
Females 
15 to 24 years 14.11 
25 to 54 years 24.89 
55 years and over 24.19 
1 Territory age- and sex-specific wage rates were unavailable from the Labour Force Survey, average territory-
specific wage rate was used instead, see table 16. 
http://www5.statcan.gc.ca/cansim/a26?lang=eng&id=2820074 
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Table 16. Average provincial wage rates (2016 CAD). 
Province Average wage rate (2016 CAD) 
Newfoundland 24.90 
Prince Edward Island 20.43 
Nova Scotia 21.55 
New Brunswick 21.51 
Quebec 23.06 
Ontario 23.68 
Manitoba 22.72 
Saskatchewan 25.60 
Alberta 26.52 
British Columbia 23.85 
Yukon 26.55 
Northwest Territories 31.28 
Nunavut 30.74 
http://www.statcan.gc.ca/tables-tableaux/sum-som/l01/cst01/labr80-eng.htm 
 
 
 
Table 17. Sensitivity analysis of direct, indirect, and total costs 
incurred (2016 CAD), for all donors (n = 912) using 2016 
provincial wage rates. 
Cost type 
Costs incurred, all donors (CAD) 
Mean (SD) Median (25th-75th percentile) 
Direct 2110 (2505) 1302 (581-2674) 
Indirect 2424 (4882) 22 (0-2617) 
Total 4535 (5573) 2565 (1066-5916) 
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Table 18. Inflation rates used to standardize costs to 
the year 2016 using Canada's Consumer Price Index. 
 
Year of Surgery Inflation Rate 
2009 10.9% 
2010 9.3% 
2011 6.6% 
2012 5.2% 
2013 4.3% 
2014 2.5% 
2015 1.4% 
http://www.statcan.gc.ca/tables-tableaux/sum-
som/l01/cst01/econ46a-eng.htm 
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Appendix F: Multiple imputation diagnostics 
 
Figure 8. Distribution of imputed, observed, and completed values for "Number of Trips" across all 20 imputation sets. 100 of 912 values were imputed. 
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Figure 9. Distribution of imputed, observed, and completed values for "Hospital Accommodation Cost" across all 20 imputation sets. 103 of 912 values were 
imputed. 
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Figure 10. Distribution of imputed, observed, and completed values for "Nights in Hotels" across all 20 imputation sets. 95 of 912 values were imputed. 
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Figure 11. Distribution of imputed, observed, and completed values for "Friends/Family Accommodation Costs" across all 20 imputation sets. 99 of 912 
values were imputed. 
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Figure 12. Distribution of imputed, observed, and completed values for “Parking Costs” across all 20 imputation sets. 104 of 912 values were imputed. 
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Figure 13. Distribution of imputed, observed, and completed values for "Days Off Without Pay" across all 20 imputation sets. 107 of 912 values were imputed. 
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Figure 14 Distribution of imputed, observed, and completed values for "Unable to Perform Household Activities Costs" across all 20 imputation sets. 119 of 
912 values were imputed. 
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Figure 15. Distribution of imputed, observed, and completed values for "Unable to Care for Dependents Costs" across all 20 imputation sets. 118 of 912 
values were imputed. 
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Figure 16. Distribution of imputed, observed, and completed values for "Medication Costs" across all 20 imputation sets. 104 of 912 values were imputed. 
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Appendix G: GLM – model diagnostics and goodness of fit 
Figure 17. a) GLM diagnostic output b) Normal probability plot assessing deviance residuals for models estimating effect of donation-
type groups on direct costs. 
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a) b) 
 
 
 
Figure 18. a) GLM diagnostic output b) Normal probability plot assessing deviance residuals for models estimating effect of donation-type 
groups on indirect costs. 
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a) b) 
 
 
 
Figure 19. a) GLM diagnostic output b) Normal probability plot assessing deviance residuals for models estimating effect of donation-type 
groups on total costs. 
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a) b) 
 
 
 
Figure 20. a) GLM diagnostic output b) Normal probability plot assessing deviance residuals for models estimating effect of relationship-type 
groups on direct costs. 
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a) b) 
 
 
Figure 21. a) GLM diagnostic output b) Normal probability plot assessing deviance residuals for models estimating effect of relationship-type 
groups on indirect costs. 
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a) b) 
 
 
 
Figure 22. a) GLM diagnostic output b) Normal probability plot assessing deviance residuals for models estimating effect of relationship-type 
groups on total costs. 
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Table 19. Complete-case analysis of direct resource use for all donors, from 3-month economic assessment (2016 CAD). 
Cost category Description 
Donors 
reporting 
resource, 
 n (%)2 
Resource use3 Costs
 for donors reporting expense 
(CAD) 
Costs for all donors, n = 912 
(CAD) 
Units Median (IQR) Average (SD) 
Median  
(IQR) Average (SD) Median (IQR) 
Travel Ground travel 726 (89%) # Return trips 10 (7-15) 1070 (1584) 500 (190-1192) 957 (1534) 402 (127-1116) 
Air travel 173 (21%) # Return trips 1 (1-2) 637 (458) 562 (324-744) 134 (334) 0 (0-0) 
Parking1 716 (89%) # Days of 
paid parking 
7 (4-11) 139 (296) 104 (55-164) 122 (281) 89 (42-158) 
Accommodation Family and 
friends1 
287 (35%) # Nights 6 (3-12) 766 (1439) 315 (158-765) 197 (802) 0 (0-31) 
Non-hospital 
paid 
339 (41%) # Nights 5 (2-8) 1150 (1818) 748 (299-1347) 477 (1300) 0 (0-565) 
Hospital1 368 (45%) # Nights 4 (3-5) 295 (530) 105 (47-336) 134 (386) 0 (0-103) 
Medication Pain medication 
or antibiotics1 
629 (77%) Drugs taken 
(yes/no) 
n/a 69 (213) 33 (21-63) 43 (171) 16 (0-46) 
1 Self-reported costs (not micro-costed). 
2 Denominator varies with participant response rate for each variable (Table 3); among donors reporting resource use (even if no out-of-pocket expenses were incurred). 
3 In donors reporting the outcome. 
Appendix H: Complete-case analyses 
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Table 20. Complete-case analysis of indirect resource use for all donors, from 3-month economic assessment (2016 CAD). 
Cost category Description 
Donors 
reporting 
resource, 
n (%)2 
Number of days3 Costs
 in donors reporting expense 
(CAD) 
Costs for all donors, n = 912 
(CAD) 
Median (IQR) Average (SD) Median (IQR) Average (SD) Median (IQR) 
Lost income Unable to work if 
employed 634 (78%) 35 (15-60) 
7827 (7439) 5974 (2481-11,748) 2441 (5511) 0 (0-2110) 
Unpaid time off 
work 251 (31%) 30 (10-56) 
Lost productivity Unable to perform 
household activities1 641 (79%) 16 (10-30)  762 (3009) 320 (205-532) 116 (1203) 0 (0-0) 
Unable to care for 
dependants1 411 (51%) 15 (9-30) 981 (2194) 328 (158-631) 95 (739) 0 (0-0) 
    1 Self-reported costs (not micro-costed). 
    2 Denominator varies with participant response rate for each variable (Table 3); among donors reporting resource use (even if no out-of-pocket expenses were incurred). 
    3 In donors reporting the outcome. 
 
Table 21. Complete-case direct, indirect, and total incurred 
costs, all donors (2016 CAD). 
Cost type 
Costs incurred (CAD) 
Mean (SD) Median (IQR) 
Direct (n = 785) 2064 (2531) 1255 (543-2603) 
Indirect (n = 780) 2595 (5652) 0 (0-2368) 
Total (n = 757) 4443 (5782) 2252 (891-5581) 
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Table 22. Complete-case unadjusted direct, indirect, and total costs (2016 CAD) incurred by living kidney donors, by donation-type group. 
 All Other Donors Non-Directed Donors Kidney Paired Donors  All Other Donors Non-Directed Donors 
Kidney Paired 
Donors 
Cost type Mean
 
(95% CI)1 
MD 
(95% CI)2 
Mean 
(95% CI)1 
MD 
(95% CI)2 
Mean  
(95% CI)1 
MD 
(95% CI)2  Median (IQR) Median (IQR) Median (IQR) 
Direct3 2013 (1833 to 2247) ref 
2140 
(1550 to 3636) 
126 
(-776 to 1030) 
2345 
(2030 to 2710) 
331  
(-257 to 919)  
1175 
(489-2505) 
2139 
(690-2709) 
2073 
(1020-3241) 
Indirect3 2686 (2250 to 3173) ref 
2579 
(1292 to 5360) 
-107 
(-2004 to 1790) 
2044 
(1424 to 2994) 
-642 
(-1598 to 314)  
0 
(0-2411) 
0 
(0-2619) 
0 
(0-2080) 
Total3 4728 (4249 to 5286) ref 
4778 
(3081 to 7665) 
50 
(-2177 to 2278) 
4457 
(3681 to 5625) 
-271 
(-1542 to 1001)  
2152 
(859-5886) 
2678 
(1008-4772) 
2914 
(1578-5869) 
1 Bootstrapped mean and 95% confidence interval. 
     2 MD = mean difference, as marginal effect from univariate generalized linear model. 
3 Number of donors varies by response rate (Table 20); Direct (Others = 644, Non-Directed = 35, Paired = 105); Indirect (Others = 640, Non-Directed = 35, Paired = 105); Total (Others = 621, 
Non-Directed = 34, Paired = 102). 
 
 
Table 23. Complete-case unadjusted direct, indirect, and total costs (2016 CAD) incurred by living kidney donors, by relationship-type group. 
 Spousal Donors Closely Related Donors Unrelated Donors  Spousal Donors Closely Related Donors 
Unrelated 
Donors 
Cost type Mean
 
(95% CI)1 
MD 
(95% CI)2 
Mean 
(95% CI) 1 
MD 
(95% CI)2 
Mean  
(95% CI) 1 
MD 
(95% CI)2  Median (IQR) Median (IQR) Median (IQR) 
Direct4 2468 (1998 to 3312) ref 
1884 
(1659 to 2173) 
-584 
(-1191 to 24) 
1940 
(1629 to 2382) 
-528 
(-1189 to 133)  
1322 
(529-2523) 
1116 
(486-2555) 
1161 
(465-2376) 
Indirect4 3012 (2058 to 4779) ref 
2892 
(2311 to 3550) 
-120 
(-1449 to 1210) 
2041 
(1535 to 2888) 
-972 
(-2302 to 359)  
0 
(0-2597) 
0 
(0-2422) 
0 
(0-2129) 
Total4 5471 (4286 to 7279) ref 
4820 
(4175 to 5519) 
-650 
(-2166 to 865) 
4017 
(3306 to 4939) 
-1454 
(-3031 to 123)  
1879 
(1022-6846) 
2187 
(787-5831) 
2215 
(904-5165) 
1 Bootstrapped mean and 95% confidence interval. 
2 MD = mean difference, as marginal effect from univariate generalized linear model. 
3 Among donors not participating in non-directed or kidney paired donations. 
4 Number of donors varies by response rate (Table 20); Direct (Spousal = 126, Closely = 341, Unrelated = 177); Indirect (Spousal = 121, Closely = 347, Unrelated = 172); Total (Spousal = 119, 
Closely = 334, Unrelated = 168). 
116 
 
 
Table 24. Complete-case adjusted1 average marginal effects of demographic variables on direct, indirect, and total 
costs (2016 CAD) incurred by living kidney donors (n = 821). 
 
Variable 
Direct costs (CAD) Indirect costs (CAD) Total costs (CAD) 
Marginal effect 
(95% CI) p 
Marginal effect 
(95% CI) p 
Marginal effect 
(95% CI) p 
Donation-type       
All other donors ref  ref  ref  
Non-directed donors -246 (-867 to 376) 0.44 -421 (-1328 to 486) 0.36 -980 (-1959 to 0) 0.05 
Kidney paired donors 369 (-118 to 856) 0.14 39 (-800 to 877) 0.93 483 (-618 to 1584) 0.39 
Relationship-type2       
Spousal donors ref  ref  ref  
Closely related donors -333 (-797 to 131) 0.16 -749 (-2241 to 744) 0.33 -1043 (-2311 to 224) 0.11 
Unrelated donors -77 (-921 to 767) 0.86 -1443 (-2458 to -428) 0.005 -1528 (-2818 to -238) 0.02 
Distance from centre       
<100 km ref  ref  ref  
 ≥100 km 2478 (2040 to 2915) <0.001 -588 (-1461 to 285) 0.19 2019 (1105 to 2934) <0.001 
Sex       
Male ref  ref  ref  
Female -260 (-728 to 208) 0.28 -6 (-858 to 846) 0.99 104 (-779 to 988) 0.82 
Age       
    18 to 35 ref  ref  ref  
    35 to 54 739 (453 to 1026) <0.001 -788 (-2133 to 557) 0.25 63 (-1299 to 1426) 0.93 
    55+ 1029 (540 to 1517) <0.001 -1650 (-2756 to -543) 0.003 -221 (-1267 to 824) 0.68 
Race       
White ref  ref  Ref  
Non-White -143 (-616 to 332) 0.56 -625 (-1656 to 406) 0.24 -311 (-1255 to 633) 0.52 
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Variable 
Direct costs (CAD) Indirect costs (CAD) Total costs (CAD) 
Marginal effect 
(95% CI) p 
Marginal effect 
(95% CI) p 
Marginal effect 
(95% CI) p 
Income       
 <$20,000 ref  ref  ref  
$20,000 to $40,000 1314 (617 to 2011) <0.001 890 (-2193 to 3973) 0.57 2674 (-310 to 5657) 0.08 
$40,000 to $60,000 1208 (594 to 1822) <0.001 -855 (-3944 to 2234) 0.59 603 (-2406 to 3613) 0.69 
$60,000 to $80,000 1254 (594 to 1915) <0.001 -308 (-3557 to 2941) 0.85 1309 (-1532 to 4151) 0.37 
$80,000 to $100,000 623 (166 to 1081) 0.008 -1730 (-4614 to 1154) 0.24 -572 (-3248 to 2285) 0.70 
>$100,000 597 (233 to 961) 0.001 -1708 (-4260 to 844) 0.19 -771 (-2963 to 1421) 0.49 
Employment status       
Employed ref  ref  ref  
Unemployed -820 (-1424 to -215) 0.008 -1822 (-3103 to -541) 0.005 -2357 (-3969 to -746) 0.004 
Retired -246 (-649 to 157) 0.23 -2347 (-3004 to -1689) <0.001 -2157 (-3030 to -1284) <0.001 
Other 267 (-544 to 1007) 0.56 -101 (-2217 to 2016) 0.93 -26 (-2325 to 2273) 0.98 
Province of transplant 
centre       
Ontario ref  ref  ref  
Alberta -565 (-1022 to -109) 0.02 161 (-1304 to 1626) 0.83 -125 (-1575 to 1326) 0.87 
British Columbia 142 (-258 to 542) 0.49 -371 (-1355 to 614) 0.46 -54 (-1076 to 968) 0.92 
Manitoba -966 (-1494 to -439) <0.001 385 (-2071 to 2842) 0.76 -368 (-2611 to 1876) 0.75 
Nova Scotia -185 (-811 to 442) 0.56 74 (-2279 to 2427) 0.95 50 (-2363 to 2463) 0.97 
Quebec 902 (-406 to 2211) 0.18 917 (-1721 to 3555) 0.50 1940 (-1040 to 4920) 0.20 
1 Adjusted for age, sex, income, Clavien score, and transplant centre. 
2 Among donors not participating in non-directed or kidney paired donations. 
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Appendix I: STROBE checklist for reporting of cohort studies 
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